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 Abstract 
 
The chemical composition of the essential oils of five different Plectranthus species 
has been determined. The major components in Plectranthus graveolens and Plectranthus 
nitidus are diterpenes. Plectranthus suaveolens essential oil contains mostly mono-, and 
sesquiterpenes and the major components are β-cedrene, 1,10-di-epi-cubenol and camphor 
with 51.49%, 18.22% and 20.08% of relative distribution, respectively. The oil of 
Plectranthus sp. ‘Hahn Tableland’ contains mostly monoterpenes with δ-3-carene and 
limonene as major components with 39.08% and 15.79% of relative distribution. Ornamental 
Plectranthus oil contains mono- and sesquiterpenes with carvacrol and δ-3-carene as the 
major components with 23.47% and 20.68% relative distribution, respectively. 
 The oils were screened for antioxidant and cytotoxic activity. The antioxidant activity 
was determined by the ORAC assay and the highest antioxidant activity was observed from 
ornamental Plectranthus (2215 ± 377 μmol TE/g), which was attributed to its high carvacrol 
content.  Cytotoxic activity was investigated against P388 mammalian cell line with curcumin 
and chlorambucil as positive controls. Highest activity was observed from P. nitidus with IC50 
value of 32 μg/mL, followed by P. graveolens and P. suaveolens with IC50 values of 60 
μg/mL and 61 μg/mL, respectively. Cytotoxic activity of P.nitidus was attributed to its 
diterpene content, but because of time and material restraints no closer investigation has been 
done. 
 Fractionation of the Plectranthus sp. ‘Hahn Tableland’ was carried out using SPE. 
Fractions were screened for antioxidant and cytotoxic activity and fraction P4B-D showed the 
highest antioxidant activity of 2368 μmol TE/g, which was attributed to its carvacrol content. 
Fraction P4B-F was the most cytotoxic against P388 cell line and had IC50 of 29 μg/mL, 
which was attributed to its intermedeol (11-selinen-4-ol; (4β,5β,7β,10α)-form) content. 
Further fractionation was done by preparative HPLC and 6 components were isolated: 
carvone; carvacrol; 3,6,6-trimethyl-2,4-cycloheptadien-1-one; 3-caren-2-one; m-cymen-8-ol; 
and m-mentha-4,6-dien-8-ol. The compounds 3,6,6-trimethyl-2,4-cycloheptadien-1-one, m-
cymen-8-ol and m-mentha-4,6-dien-8-ol have not been reported in the genus before. 3-Caren-
2-one was not originally found in the oil but is possibly an oxidation product of δ-3-carene, 
the major compound of the oil.  
 Fractionation of the red oil of P. nitidus has been carried out by preparative HPLC and 
the fractions were subjected to LCMS analysis and two compounds were isolated: a red 
crystal and a yellow oil. The red crystal was identified as 12-hydroxy-6,8,12-abietatriene-
 iv
11,14-dione ([M+1]+=315.2) and it is also the major component in the oil. The yellow oil was 
tentatively identified as 7,9(11)-abietadiene-13-ol.  
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Zusammenfassung 
Diese Arbeit befasst sich mit der Untersuchung der chemischen Zusammensetzung 
von den ätherischen Ölen aus fünf Plectranthus species. Die Hauptkomponenten in den 
ätherischen Ölen von Plectranthus graveolens und Plectranthus nitidus waren Diterpene. Das 
Öl vom Plectranthus suaveolens enthielt meistens Mono- und Sesquiterpene mit den 
Hauptinhaltsstoffen β-Cedren, 1,10-di-epi-Cubenol und Campher mit 51.49%, 18.22% bzw. 
20.08% relativer Verteilung. In Plectranthus sp. ‘Hahn Tableland’ waren hauptsächlich 
Monoterpene vorhanden mit δ-3-Caren und Limonen als Hauptkomponenten mit 39.08% 
bzw. 15.79% relativer Verteilung. Im ätherischen Öl des dekorativen Plectranthus waren 
Mono- und Sesquiterpene mit Carvacrol und δ-3-Caren die Hauptinhaltstoffe mit 23.47% 
bzw. 20.68% relativer Verteilung. 
  Die Öle wurden auf zytotoxische und antioxidative Aktivität geprüft. Die 
antioxidative Aktivität wurde mittels ORAC-Assay ermittelt und die höchsten Werte wurden 
mit dem Öl des dekorativem Plectranthus beobachtet (2215 ± 377 μmol TE/g). Diese hohe 
Aktivität wurde dem hohen Gehalt an Carvacrol zugeschrieben. Die zytotoxische Aktivität 
wurde gegen P388 Zellen geprüft. Als Kontrollsubstanzen wurden Curcumin und 
Chlorambucil verwendet. Ebenfalls eine sehr starke Aktivität wurde mit dem Öl von P. 
nitidus beobachtet, mit einem IC50 Wert von 32 μg/mL. P. graveolens und P. suaveolens 
erwiesen sich mit IC50 Werten von 60 μg/mL bzw. 61 μg/mL weniger aktiv. Die zytotoxische 
Aktivität von P. nitidus wurde seinem Diterpen-Gehalt zugeordnet. Auf Grund der Zeit- und 
Materialbeschränkung konnte aber eine detaillierte Analyse nicht mehr durchgeführt werden. 
 Die Fraktionierung des ätherischen Öls von Plectranthus sp. ‘Hahn Tableland’ wurde 
mittels SPE durchgeführt. Die Fraktionen wurden auf antioxidative und zytotoxische Aktivität 
geprüft und die Fraktion P4B-D zeigte den höchsten Wert von 2368 μmol TE/g. Das wurde 
dem hohen Gehalt dieser Fraktion an Carvacrol zugeordnet. Auch die Fraktion P4B-F erwies 
sich sehr stark zytotoxisch aktiv gegen den P388 Zellen (IC50 lag bei 29 μg/mL), was ihrem 
Gehalt an Intermedeol (11-Selinen-4-ol; (4β,5β,7β,10α)-Form) zugeordnet wurde. Die weitere 
Fraktionierung wurde mittels HPLC durchgeführt und so die folgenden 6 Komponenten 
isoliert: Carvon; Carvacrol; 3,6,6-Trimethyl-2,4-cycloheptadien-1-on; 3-Caren-2-on; m-
Cymen-8-ol; und m-Mentha-4,6-dien-8-ol. Die Komponenten 3,6,6-Trimethyl-2,4-
cycloheptadien-1-on, m-Cymen-8-ol und m-Mentha-4,6-dien-8-ol wurden bis jetzt in dieser 
Gattung nicht beschrieben. 3-Caren-2-on war ursprünglich nicht im Öl zu finden aber es ist 
wahrscheinlich ein oxidatives Produkt der Hauptkomponente δ-3-Caren.  
 vi
 Die Fraktionierung des roten Öls aus P. nitidus wurde mittels HPLC durchgeführt, 
dann wurden die Fraktionen mittels LCMS untersucht und zwei Komponenten isoliert: der 
rote Kristall und das gelbe Öl. Der rote Kristall - die Hauptkomponente des betreffenden Öls - 
wurde als 12-Hydroxy-6,8,12-abietatrien-11,14-dion ([M+1]+=315.2) identifiziert. Dem 
gelben Öl kommt vorläufig die Strukturformel von 7,9(11)-Abietadien-13-ol zu. 
 
 vii
 
Acknowledgments 
 
Firstly, I would like to thank Professor Gerhard Buchbauer for making it possible for me 
to do the thesis at the SCU, and for being very helpful about prioritizing my work and 
correcting it as soon as possible. I really appreciate his friendly advice and encouragement at 
the very beginning of my studies in Vienna, which made my life much easier. I`m very 
flattered that I did my thesis under his supervision.   
 
My special thanks is going to Dr. Myrna Deseo for her excellent guidance throughout this 
project, the support and encouragement she gave me, sharing my passion about the work and 
for motivating me through the challenging times, for being a great teacher but also a friend, 
and for making this whole experience very rewarding and enjoyable for me. I would also like 
to thank her for running and analyzing my NMR spectra and taking her time to stay afterhours 
just to help me finish on time. 
 
I would like to thank Paul Connellan for his inspirational words of wisdom and Dion 
Thompson for his help with pharmacology assays and both of them for creating a pleasant 
atmosphere and a friendly working environment. 
Thanks to Lei Liu for his help with preparative HPLC and patience with the many questions I 
asked time and time again.  
 
Thanks to Linda Banbury for taking her time to help me with all the small problems I had 
while writing this thesis, to Narin Tongmar and Chris Jenkins for relaxing and funny chats, 
special thanks to Hao Wang for letting me use his coffee cup for my soup, and Chrystal Wang 
for her ever-smiling face. Also my special thanks go to the rest of the staff from CPP for their 
friendly attitude and help whenever they saw me looking lost or confused.    
 
My very special thanks go to Žunić family for their hospitality, for making me feel like 
home and treating me as a part of their family.  
 
I`m very grateful for the opportunity to have met great people such as Myralyn Abasolo, 
Gelenta Salopuka, Tim Sexton and Adlin Afzan with whom I spent more or less every lunch 
break at the Plaza, and without whom this whole experience would not be as fun. 
 
 viii
Although words could never express how grateful and lucky I am for having the best 
parents and brothers in the whole world, I would like to thank my mother Draga, father Zoran, 
and brothers Nikola and Ilija for being always there for me, for their love, support, and 
believing in me, especially through tough times. Without them I would have never achieved 
as much as I have.  
 
 ix
Publications Arising from this 
Research 
 
Elena Pasoski, Leema Marangattil, Myrna A.Deseo, David N. Leach and Paul Forster,  
Preliminary investigation into the phytochemical and pharmacological aspects of 
Plectranthus sp., Royal Australian Chemical Institute (RACI) Natural Products Chemistry 
Group Annual One Day Symposium, University of New Castle, New Castle, NSW, 
Australia, 2nd October 2009. 
 
 
 x
Table of Contents 
 
 
1.  Introduction....................................................................................................... 17 
1.1.  Aims and overview of the thesis................................................................. 17 
1.2.  An overview of family Lamiaceae and genus Plectranthus....................... 17 
1.3.  Traditional medicinal uses of Plectranthus species ................................... 20 
1.4.  Chemistry and biological activity of the components ................................ 22 
1.5.  Plectranthus sp. ‘Hahn Tableland’............................................................. 25 
1.6.  Plectranthus nitidus.................................................................................... 26 
1.7.  Pharmacological assays .............................................................................. 26 
1.7.1.  Antioxidant activity .................................................................................... 26 
1.7.2.  Cytotoxic activity ....................................................................................... 26 
2.  Materials and methods ..................................................................................... 28 
2.1.  Oil distillation ............................................................................................. 28 
2.2.  Phytochemistry ........................................................................................... 29 
2.2.1.  Gas Chromatography – Mass Spectroscopy (GC-MS)............................... 29 
2.2.1.1.  GC-MS technical information .................................................................... 29 
2.2.1.2.  Identification of components ...................................................................... 29 
2.2.2.  Solid-Phase-Extraction (SPE) .................................................................... 31 
2.2.3.  Liquid Chromatography- Mass Spectrometry (LC-MS) ............................ 32 
2.2.4.  High Performance Liquid Chromatography (HPLC) ................................. 33 
2.2.4.1. Analytical HPLC ........................................................................................ 33 
2.2.4.2.  Preparative HPLC....................................................................................... 35 
2.2.5.  Nuclear Magnetic Resonance (NMR) Spectroscopy.................................. 37 
2.3.  Pharmacology ............................................................................................. 37 
2.3.1.  Oxygen Radical Absorbance Capacity (ORAC) ........................................ 37 
2.3.1.1.  Reagents and materials ............................................................................... 37 
2.3.2.  Cytotoxicity ................................................................................................ 39 
2.3.2.1.  Reagents and materials ............................................................................... 40 
2.3.2.2.  Procedure.................................................................................................... 40 
3.  Comparison of the oil profiles.......................................................................... 42 
 xi
3.1.  Phytochemical comparison of the oil profiles ............................................ 42 
3.1.1.  Plectranthus graveolens (P1) ..................................................................... 42 
3.1.2.  Plectranthus suaveolens (P2) ..................................................................... 43 
3.1.3.  Plectranthus nitidus (P3) ............................................................................ 45 
3.1.4.  Plectranthus sp. ‘Hahn Tableland’............................................................. 46 
3.1.4.1.  First distillation batch (P4A) ...................................................................... 46 
3.1.4.2.  Second distillation batch (P4B) .................................................................. 48 
3.1.5.  Ornamental Plectranthus ............................................................................ 50 
3.1.5.1.  First distillation batch (P6A) ...................................................................... 50 
3.1.5.2.  Second distillation batch (P6B) .................................................................. 52 
3.1.5.3.  Comparison of the P6A and P6B after three months period ...................... 53 
3.2.  Pharmacology of the Plectranthus oils....................................................... 55 
3.2.1.  ORAC ......................................................................................................... 55 
3.2.2.  Cytotoxicity assay ...................................................................................... 56 
4.  Plectranthus sp. ‘Hahn Tableland’: P4B......................................................... 57 
4.1.  Fractionation............................................................................................... 57 
4.2.  GC-MS and LCMS analysis of the fractions.............................................. 59 
4.2.1.  P4B-B fraction............................................................................................ 59 
4.2.2.  P4B-C fraction............................................................................................ 59 
4.2.3.  P4B-D fraction............................................................................................ 60 
4.2.4.  P4B-E fraction ............................................................................................ 63 
4.2.5.  P4B-F fraction ............................................................................................ 64 
4.2.6.  P4B-G fraction............................................................................................ 64 
4.2.7.  P4B-H fraction............................................................................................ 65 
4.2.8.  P4B-I fraction ............................................................................................. 66 
4.2.9.  P4B-J and P4B-K fractions ........................................................................ 67 
4.2.10.  P4B-L and P4B-M fractions ....................................................................... 68 
4.3.  Pharmacology of the P4B subfractions ...................................................... 68 
4.3.1.  ORAC ......................................................................................................... 68 
4.3.2.  Cytotoxicity assay ...................................................................................... 69 
4.4.  Preparative HPLC....................................................................................... 70 
4.4.1.  Fraction P4B-C........................................................................................... 70 
4.4.1.1.   Identification of P4B-C-14 as 3-caren-2-one ............................................. 71 
4.4.1.2.  Identification of P4B-C-18 as m-cymen-8-ol ............................................ 73 
 xii
4.4.2.   Fraction P4B-D.......................................................................................... 74 
4.4.2.1.  Identification of P4B-D-8 as 3,6,6-trimethyl-2,4-cycloheptadien-1-one ... 75 
4.4.2.2.  Identification of P4B-D-14 as 5-isopropenyl-2-methyl-2-cyclohexen-1-one 
(Carvone) .................................................................................................... 77 
4.4.2.3.  Identification of P4B-D-25 and P4B-D-27 as 5-isopropyl-2-methylphenol 
(Carvacrol).................................................................................................. 78 
4.4.2.4.  Identification of P4B-D-16 as m-mentha-4,6-dien-8-ol ............................. 80 
4.4.2.5.  Pharmacology of the P4B-D fractions........................................................ 81 
4.4.3.  Fraction P4B-H........................................................................................... 83 
4.4.4.  Fraction P4B-I ............................................................................................ 83 
5.  Plectranthus nitidus (P3) ................................................................................... 86 
5.1.  Preparative HPLC of P. nitidus oil (P3) ..................................................... 86 
5.1.1.  Identification of P3 crystal as 12-hydroxy-6,8,12-abietatriene-11,14-dione89 
5.1.1.1.  Identification of P3-36 as 7,9(11)-abietadiene-13-ol ................................. 90 
6.  Summary and recommendations..................................................................... 92 
 xiii
 
List of Figures 
 
Figure 1.  Typical flowers of Plectranthus [3]. ........................................................................18 
Figure 2.  Typical leaves of Plectranthus species. ...................................................................18 
Figure 3.  Plectranthus graveolens [1]. ....................................................................................19 
Figure 4.  Plectranthus suaveolens [1]. ....................................................................................19 
Figure 5.  Plectranthus nitidus (Picture by Peter Richards).....................................................20 
Figure 6.  Plectranthus sp. ‘Hahn Tableland’. .........................................................................20 
Figure 7.  Nepetoidin A (1) and B (2). .....................................................................................25 
Figure 8.  Apparatus of the steam water distillation.................................................................28 
Figure 9.  P4A-G1 fraction run with methods ELENA1-ELENA4. ........................................35 
Figure 10. Total Ion Chromatogram of freshly distilled oil of Plectranthus graveolens P1.....42 
Figure 11. Total Ion Chromatogram of freshly distilled oil of P. suaveolens P2......................44 
Figure 12. Total Ion Chromatogram of freshly distilled oil of Plectranthus nitidus P3. ..........45 
Figure 13. Total Ion Chromatogram of freshly distilled oil of P. sp. ‘Hahn Tableland’ P4A. .47 
Figure 14. Total Ion Chromatogram of freshly distilled oil of P. sp. ‘Hahn Tableland’ P4B...49 
Figure 15. Total Ion Chromatogram of freshly distilled oil of ornamental Plectranthus. ........51 
Figure 16. Total Ion Chromatogram of freshly distilled oil of ornamental Plectranthus. ........52 
Figure 17.Overlaid TIC of P4A and P4B. ................................................................................56 
Figure 18.  IC50 (μmol/mL) values of Plectranthus volatile oils (P1-P6). ................................56 
Figure 19.  Schematic representation of the fractionation of P4B. ...........................................57 
Figure 20. UV spectra at 210, 280, 360 and 500nm wavelength and LCMS profile of P4B-B 
fraction. ....................................................................................................................59 
Figure 21.  Total ion chromatogram of the P4B-C fraction. .....................................................60 
Figure 22. Total ion chromatogram of the P4B-D fraction. ......................................................61 
Figure 23. Total ion chromatogram of the P4B-E fraction. ......................................................63 
Figure 24. Total ion chromatogram of the P4B-F fraction........................................................64 
Figure 25. Total ion chromatogram of the P4B-G fraction. ......................................................65 
Figure 26. Total ion chromatogram of the P4B-H fraction. ......................................................66 
Figure 27. Total ion chromatogram of the P4B-I fraction.........................................................67 
Figure 28. Total ion chromatogram of the P4B-J and P4B-K fractions....................................67 
Figure 29. UV spectra at 210, 280, 360 and 500nm wavelength and LCMS profile of P4B-K 
and P4B-M fractions. ...............................................................................................68 
Figure 30. IC50 (μmol/mL) values of the P4B-D fractions........................................................69 
 xiv
Figure 31. Prep. HPLC Chromatogram of the P4B-C fraction (Method: ELENA5). ...............70 
Figure 32. Structure of P4B-C-14 (3-caren-2-one, CAS Registry Number: 53585-45-8). .......71 
Figure 33. GC-MS profile of the fraction P4B-C-14. ...............................................................72 
Figure 34. Structure of P4B-C-18 (m-cymen-8-ol, CAS registry number: 5208-37-7)............73 
Figure 35. GC-MS profile of the P4B-C-18 fraction. ...............................................................73 
Figure 36. HPLC Chromatogram of the P4B-D fraction (Method: ELENA5). ........................75 
Figure 37. Structure of P4B-D-8 (3,6,6-Trimethyl-2,4-cycloheptadien-1-one, CAS Registry 
Number: 2767-18-2). ...............................................................................................76 
Figure 38. Structure of the P4B-D-14 (5-isopropenyl-2-methyl-2-cyclohexen-1-one, CAS 
Registry Number: 99-49-0). .....................................................................................77 
Figure 39. GC-MS profile of the fraction P4B-D-14. ...............................................................77 
Figure 40. Structure of the P4B-D-25 (5-isopropyl-2-methylphenol,CAS Registry Number: 
499-75-2)..................................................................................................................79 
Figure 41. GC-MS profile of the fraction P4B-D-25. ...............................................................79 
Figure 42. Structure of the m-mentha-4,6-dien-8-ol. ................................................................80 
Figure 43. GC-MS profile of the fraction P4B-D-16. ...............................................................80 
Figure 44. UV spectra at 210, 280, 360 and 500nm and LCMS profile of the P4B-D-14........82 
Figure 45. Prep. HPLC Chromatogram of the P4B-H fraction (Method :ELENA-H)..............83 
Figure 46. Prep. HPLC of the P4B-I fraction (Method: ELENA6)...........................................84 
Figure 47. UV spectrum at 210nm and LCMS profile of P4B-I-13..........................................84 
Figure 48. UV spectrum at 210nm and LCMS profile of P4B-I-28..........................................85 
Figure 49. Prep. HPLC of the P3 oil (Method:ELENA-H).......................................................87 
Figure 50.Overlaid UV spectra at 210nm wavelength of the crude oil, P3-31 and P3-36. ......88 
Figure 51.Overlaid LCMS spectra of the crude oil, P3-31 and P3-36. ....................................88 
Figure 52. Structure of P3 crystal (12-hydroxy-6,8,12-abietatriene-11,14-dione)....................89 
Figure 53. LCMS profile of the P3 crystal. ...............................................................................89 
Figure 54. Structure of the P3-36 (7,9(11)-abietadiene-13-ol)..................................................90 
Figure 55. LCMS prfile of the fraction P3-36...........................................................................90 
Figure 56.Summarized pharmacology results of the Plectranthus oils....................................92 
Figure 57.  Identified compounds from P.nitidus oil shown on the UV chromatogram at 
210nm wavelength..................................................................................................94 
 
 xv
 
List of Tables 
 
Table 1.  Traditional uses of some Plectranthus species. .......................................................22 
Table 2.  Samples material ......................................................................................................28 
Table 3.  Reference standards. ................................................................................................30 
Table 4.  Hydrocarbons used in calculating KI.......................................................................31 
Table 5.  Strategy of diluting the samples/controls used in ORAC assay ..............................39 
Table 6.  Chemical profile of the Plectranthus graveolens. ...................................................43 
Table 7.  Chemical Profile of Plectranthus suaveolens. .........................................................44 
Table 8.  Chemical Profile of Plectranthus nitidus.................................................................46 
Table 9.  Chemical Profile of Plectranthus sp. ‘Hahn Tableland’ P4A..................................48 
Table 10.  Chemical profile of Plectranthus sp. ‘Hahn Tableland’ P4B. .................................50 
Table 11.  Chemical Profile of ornamental Plectranthus P6A..................................................51 
Table 12.  Chemical Profile of ornamental Plectranthus P6B..................................................53 
Table 13.  Chemical composition of P6A, P6B and change in percentage of distribution.......54 
Table 14.  ORAC values of Plectranthus oils...........................................................................55 
Table 15. SPE fractionation strategy and yields of the individual fractions (batches I, II, III 
and IV).......................................................................................................................58 
Table 16.  Chemical composition of the P4B-C fraction. .........................................................60 
Table 17.  Chemical composition of the P4B-D fraction..........................................................62 
Table 18.  Chemical composition of the P4B-E fraction. .........................................................63 
Table 19.  Chemical composition of the P4B-F fraction. .........................................................64 
Table 20.  Chemical composition of the P4B-G fraction..........................................................65 
Table 21.  Chemical composition of the P4B-H fraction..........................................................66 
Table 22.  Chemical composition of the P4B-I fraction. ..........................................................67 
Table 23.  Chemical composition of the P4B-J and P4B-K fractions.......................................68 
Table 24.  ORAC results of the P4B fractions. .........................................................................69 
Table 25.  Yields of the P4B-C fractions. .................................................................................71 
Table 26.  The 1H and 13C NMR data for P4B-C-14 (3-caren-2-one). .....................................72 
Table 27.  1H and 13C NMR data for P4B-C-18 (m-cymen-8-ol) .............................................74 
Table 28.  Yields of P4B-D subfractions. .................................................................................75 
Table 29.  1H and 13C NMR data for P4B-D-8 (3,6,6-trimethyl-2,4-cycloheptadien-1-one). ..76 
Table 30.  1H and 13C NMR data for P4B-D-14 (5-isopropenyl-2-methyl-2-cyclohexen-1-on78 
 xvi
Table 31.  1H and 13C NMR data for P4B-D-25 (5-isopropyl-2-methylphenol).......................79 
Table 32.  1H and 13C NMR data for P4B-D-16 (m-mentha-4,6-dien-8-ol). ............................81 
Table 33.  ORAC results of P4B-D fractions............................................................................82 
Table 34.  Yields of the P3-Fractions........................................................................................87 
Table 35.  The 1H and 13C NMR data for P3-36 (13-hydroxyl-7,9-abietadiene)......................91 
Table 36.  Summarized table of the Plectranthus species oil profiles ......................................92 
Table 37.  Isolated compounds from the P4B oil......................................................................93 
 
 
 
 17 
1. Introduction 
1.1. Aims and overview of the thesis 
Plectranthus is one of the genera of Lamiaceae family, subfamily Nepetoideae. It comprises 
about 300 species worldwide [1]. They usually inhabit the southern hemisphere and are 
typical in sub-Saharan Africa, India, the Indonesian archipelago, Australia and some Pacific 
Islands. In Australia, 28 species can be found, 22 are endemic, and 6 are introduced [2]. 
Although Plectranthus species have been used in traditional medicine for a long time, some 
of them are yet to be described.  The lack of present information on Australian Plectranthus 
species renders this genus interesting for further investigation in botanical, phytochemical and 
pharmacological aspects. Plectranthus sp. ‘Hahn Tableland’ is a species that has not been 
described yet, and it is typical for Hahn Tableland region of north-east Queensland. 
Plectranthus nitidus occurs in south-eastern Queensland and north-eastern New South Wales, 
and although it has been described, little is known about this species. 
The aims of this thesis were: 
1. To determine chemical composition of the essential oils of five different Plectranthus 
species  
2. To screen the volatile oils for antioxidant and cytotoxic activity 
3. To investigate the active compounds of the Plectranthus sp. ‘Hahn Tableland’ and 
Plectranthus nitidus oil using bioactivity-guided fractionation.  
1.2. An overview of family Lamiaceae and genus Plectranthus 
Lamiaceae, also known as mint-family, is a large plant family containing 236 genera with 
7173 species worldwide. They occur almost throughout the world, except of the coldest 
regions of high latitude and altitude. In Australia 44 genera were described containing 750 
species in all states. They usually appear as shrubs and herbs with tetragonal stems and 
opposite leaves. The original name of the family was Labiateae (labia is the Latin for “lip”), 
which was given to this family because of the shape of its flowers. They are zygomorphic, 
and the corolla usually has an upper and lower lip. The upper lip possesses two lobes and 
forms a hood over the lower lip, which has three lobes. Flowers occur mostly in heads, spikes, 
cymes or in panicles.  
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Figure 1. Typical flowers of Plectranthus [3]. 
 
They are usually aromatic plants and some of the popular kitchen herbs like rosemary or 
oregano belong to this family. Lots of them are used in traditional medicine because of their 
antiseptic, antimicrobial and antioxidant properties. Their volatile oils are commonly used in 
aromatherapy. Plectranthus species occur as herbs, subshrubs or shrubs. They are often 
succulent and with opposite leaves. Inflorescence is terminal or in the upper leaf axils and 
flowers are in compact cymose clusters.  
            
Figure 2. Typical leaves of Plectranthus species. 
 
In Australia they are typically found in the east coast of NSW and Qld, mostly on rocky 
outcrops and creek-beds. In this study five different oils from Plectranthus species that grow 
along east Australian coast have been profiled.   
Plectranthus graveolens (Latin = “strong smelling”) is a small spreading shrub with strongly 
aromatic toothed leaves and violet flowers. Branches and leaves are densely covered with 
hairs with orange-red sessile glands (Figure 3). 
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Figure 3. Plectranthus graveolens [2]. 
 
The volatile oil is intense red coloured with strong aromatic smell. It is distributed widely 
from south-east NSW to north-east Qld. 
Plectranthus suaveolens is a sweetly aromatic shrub to 80 centimeters in height. The 
branches and leaves are densely covered with short white, retorse hairs and many shorter 
gland-tipped hairs. Corolla is blue to violet and hairy as well (Figure 4). The volatile oil is 
orange with pleasant aromatic smell. 
They usually inhabit rocky and shallow soil sites and are found in the north coast and northern 
Tablelands districts of NSW, but also occur in the Darling Downs and Moreton Districts of 
Queensland. 
      
Figure 4. Plectranthus suaveolens [2]. 
 
Plectranthus nitidus (Nightcap Plectranthus) is a small shrub that grows 30–150 cm tall. The 
leaves are fleshy and rounded with a green upper and a purple lower surface. The branches are 
erect and sparsely covered with short hairs. The flowers are lilac to blue and have a long 
lower lip (Figure 5). Plectranthus nitidus occurs on rocky cliff faces or amongst rocky 
outcrops and is restricted to south-east Queensland and north-east NSW where it occurs from 
the Nightcap Range north to the McPherson Ranges.  
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Figure 5. Plectranthus nitidus (Picture by Peter Richards). 
 
Plectranthus sp. ‘Hahn Tableland’ 
P. sp ‘Hahn Tableland’ was first found in the Hahn Tableland region of north Queensland 
[4].It is and aromatic plant with a pleasant scent. The leaves are succulent and covered with 
fine hairs on the both sides (Figure 6). This species has not yet been botanically described. 
   
Figure 6. Plectranthus sp. ‘Hahn Tableland’. 
Ornamental Plectranthus 
Ornamental Plectranthus species investigated in this study is known, but has not yet been 
identified.  
1.3. Traditional medicinal uses of Plectranthus species 
Traditional medicine has been used in many cultures for thousands of years to prevent and 
treat different medical conditions. Medicinal herbs were found in the personal effects of an 
"ice man", whose body was frozen in the Austrian Alps for more than five thousand years. 
Even nowadays in some Asian and African countries traditional medicine represents the 
primary health care and it is getting more and more popular in western society as well. 
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According to WHO 70% to 80% of the population in many developed countries has used 
some form of alternative or complementary medicine. 
Herbal treatments are the most popular form of traditional medicine and are very profitable in 
the international marketplace. Revenue from sales of herbal products reached 5 billion US$ in 
2003-2004 in Western Europe, and 14 billion US$ in 2005 in China.  
Plant metabolites have a long history of use as herbal remedies, including opium, digitoxine, 
vinblastine. According to the WHO, approximately 25% of modern drugs used in the United 
States have been derived from plants which confirms that chemistry of natural products is 
very interesting and a promising research field. 
 
Plants of Plectranthus genera are well-known remedies in traditional medicine of many 
countries. They have been used for different digestive, skin and respiratory conditions, fever 
and infections, genital-urinary conditions, pain and muscular-skeletal conditions. For 
example, leaves of P. igniarius are used in Kenya to treat inflamed eyes. Numerous species 
including P. amboinicus, P. barbatus, P. caninus, P. esculentus are reported to have cytotoxic 
and anti-tumour activity and can be used in the treatment of cancer. Plectranthus barbatus is 
one of the most used Plectranthus species. For example, its essential oil exhibits anti-allergic 
activities through passive cutaneous anaphylaxis inhibition. It is also used for various 
digestive disorders like nausea, stomachache, and in Brazil even to treat gastritis. The 
essential oil of P.sylvestris is used to treat skin diseases. P. mandalensis is used in Malawi to 
treat depression and in India P. vettiveroides is used as a stimulant [1]. 
Some of the plants and their usage are listed in Table 1.  
Except in traditional medicine these plants are also used as ornamentals (P. glabratus, P. 
forsteri), kitchen spices (P. amboinicus, also known as Mexican oregano), food (Plectranthus 
esculentus) or food additives. 
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Table 1. Traditional uses of some Plectranthus species. 
1.4. Chemistry and biological activity of the components 
This broad spectrum of traditional uses makes it interesting to investigate the chemistry of the 
genus, especially its secondary metabolites as they play an important role in protecting the 
plant against herbivores and microorganisms or in attracting pollinating or seed dispersing 
animals, and therefore have variety of biological activities [5]. 
Essential oils are big and diverse group of secondary metabolites that represent a mixture of 
terpenoid molecules. Terpenoids are made in a plant via mevalonic acid biosynthetic pathway 
(sesquiterpene) and via the xylulose-pyruvate-pathway (mono- and diterpenes) and usually 
stored in resin ducts, glandular trichomes or oil cells.  Because of their volatile and lipophilic 
nature essential oils could be easily absorbed in human body via respiratory system, or via 
skin. Once absorbed they bind to the target molecules. Different constituents of an essential 
oil could have different target molecules and therefore different activity, which could make 
the oil very interesting in therapeutic sense, since it could fulfil various effects simultaneously 
[6]. Although they are widely in use, especially in cosmetic, flavour and fragrance industry, 
their therapeutic effects (anti-inflammatory, anti-tumour, antioxidant) and mechanism of 
action have not yet been well investigated.  
 
The genus Plectranthus belongs to Nepetoideae subfamily, the biggest of all Lamiaceae 
subfamilies, comprising ca. 3500 species in 105 genera. This subfamily showes specific 
secondary metabolites chemistry that is different to the other Lamiaceae subfamilies. The 
Species  Part used  Area used  Used for  
P. barbatus  leaves  Africa, Brazil  stomachache  
P. floribundus  root tuber  Nigeria  food  
P. amboinicus  seed oil Polynesia acute oedematous 
otitis acuta 
P. asirensis  whole leaf  Saudi Arabia  Antiseptic 
wound-dressing  
P.  sylvestris volatile oil  Rwanda  skin diseases 
P.  caninus  root extract Kenya coughs 
P. vettiverioides  plant remedy  Indian ayurvedic  vomiting and nausea 
P. congestus  Australia internal complaints 
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essential oils contain monoterpenoids instead of monoterpenoid iridoid glycosides. 
Phenylpropanoid chemistry produces components that are more non-polar comparing to other 
families. An explanation why these changes took place could be found in wide spectra of 
activities in their essential oils (antifungal, anti-insecticidal) and phenolic components 
(antioxidant) offering these species advantages in natural selection during evolution [7]. 
Plectranthus is an essential-oil rich genus with > 0.5% volatile oil on a dry weight basis [8]. 
Secondary metabolites that can be found in the oils include mono-, sesqui- and diterpenes and 
phenolics.   
 
Mono- and sesquiterpenes are usually the major components of the volatile oil. The 
therapeutic effects of some of these compounds are well-known. Limonene is found to be 
tumour preventive, linalool sedative and anti-infectious, pinene and p-cymene to relieve 
muscular aches [6]. But still only a few investigations have been carried out on the 
relationship of biological activity of monoterpenoids and traditional uses of the plants. 
    
OH
   
limonene  p-cymene  linalool  myrcene 
 
Some of the sesquiterpenes that have been reported in the genus are β-caryophyllene in P. 
barbadus and P. sylvestris, and humulene in P. barbatus, and 15-hydroxyspathulenol in P. 
fruticosus. They are an interesting group of components with various therapeutic properties 
such as antitumor [9], anti-inflammatory [10] and antiviral [11] but yet not well studied in this 
genus.   
     
β-caryophyllene    α-humulene 
  
Diterpenoids are the major and very common group of second metabolites in the species. 
They are usually highly modified abietanoids. The other major group contains mainly labdane 
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diterpenoids. Phyllocladanes, ent-kaurenes and a seco-kaurene were also found in the genus. 
Clerodane diterpenoids, which are present in Salvia, are not found in Plectranthus.  
     
Labdane type     Abietane type 
 
The majority of studies on phytochemical profiles of Plectranthus oils were concentrated on 
activity and isolation of diterpenes. Royleanone and coleone are abietane diterpene found in 
P. grandidentatus, and were reported to have activity on T-, B-lymphocyte proliferation [12]. 
In the same plant horminone (7,12-dihydroxy-8,12-abietadiene-11,14-dione) is reported to be 
antibacterial against Staphylococcus aureus [13]. Antiviral activity against Herpes simplex 
type II was found in acetone extract of the root of P. hereroensis due to the presence of 16-
acetoxy-7α,12-dihydroxy-8,12-abietadiene-11,14-dione [14]. Ferrungiol, sugiol, 6,7-
dehydroroyleanone are reported to have anti-SARS-CoV activity [15].  
Labdane diterpenes were found in P. barbatus and P. ornatus and include forskolin and 
plectrornatin. Forskolin was found to directly activate adenyl cyclase hereby influence cAMP 
concentration [1]. This could explain traditional uses of this plant in diverse gastric and 
muscular conditions. It is also found to have antimetastatic activity against lung cancer in 
mice [16]. 
Phenolic compounds and their antioxidative activity in Plectranthus genus have not been well 
studied. In Plectranthus ambiguus 5,6-dihydroxy-7,4-dimethoxyflavone (ladanein) [17] has 
been reported. Grayer et al. reported two non-flavonoid phenolics –Nepetoidin A (1) and B 
(2) that are shown in Figure 7. They seem to be present in nearly every Nepetoideae species. 
Nepetoidin B showed strong antioxidant activity and both components had antifungal 
properties [7].  
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    Figure 7. Nepetoidin A (1) and B (2). 
 
Lukhoba and Abdel-Mogib both concluded that not much research has been done on 
chemistry of Plectranthus, especially on biologically active mono- and sesquiterpenes. All 
this makes any further investigation in taxonomy, chemistry and pharmacology of this genus 
very interesting and worthwhile.  
1.5. Plectranthus sp. ‘Hahn Tableland’ 
There has been not a lot research done on chemistry on Plectranthus sp. ‘Hahn Tableland’. 
Rosikari et al. have worked on insecticidal activity of the crude methanol extract and its 
water, ethyl-acetate and hexane partitions. Interestingly, they have noticed two compounds in 
methanol extract that were not present in other 26 Plectranthus species investigated in that 
study. UV and mass spectra of these compounds seemed to be similar to the patterns of 
flavonoid glycoside. These extracts showed high toxicity against Tetranychus. urticae and 
Heliothrips haemorrhoidalis and they were more toxic than extract of P.graveolens. Activity 
against T.urticae was attributed to the non-polar constituents of the extract. As a fresh residue 
it had an ovicidal and oviposition inhibition effect. The phenomenon that the ethyl acetate 
partition was only mildly toxic to T. urticae but highly toxic to cells was observed in P. sp. 
‘Hahn Tableland’ and P. graveolens as well and may be due to the presence of abietane 
diterpenes [4]. 
Marangattil has done some preliminary investigation in chemical composition and antioxidant 
and cytotoxic activity of the plant`s volatile oil. GC profile showed mostly monoterpenes: 
carvacrole, eucarvone, limonene, 3-carene, α-pinene, α-phellandrene and p-cymene. The oil 
did not seem to have significant antioxidant or cytotoxic activity, but some fractions showed 
better response against free radicals and P388 cells. Because of time and material constraints, 
but also because of specific nature of monoterpenes found in the oil, she did not manage to 
isolate any pure component at the time.   
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1.6. Plectranthus nitidus 
To the knowledge of the author of this thesis, there have been no studies published neither on 
phytochemistry or pharmacology of this species.  
1.7. Pharmacological assays 
Pharmacological assays were chosen accordingly to the previous reported cytotoxic, 
antioxidant and inflammatory activities in the genus. 
1.7.1. Antioxidant activity 
Antioxidants are chemicals that have scavenging activity against reactive nitrogen and oxygen 
species (RNS and ROS). RNS and ROS cause oxidative stress in the human body, damaging 
cellular membrane, proteins and DNA, and therefore play an important role in aging and 
various pathological processes. Although the body has antioxidant enzymes (superoxide 
dismutases, catalases, peroxidases, glutathione-system and others) that can neutralize these 
reactive species, their capacity can get overloaded.  Antioxidants act supportively because of 
their ability to either prevent or break the radical chain reaction [18]. Antioxidants are not 
only interesting as food supplements, but are also extensively used as preservatives in food 
and cosmetic industry, as stabilizers in fuels and lubricants and used to prevent oxidation 
processes in different polymers like plastic and rubbers. 
To measure the antioxidant activity the Oxygen Radical Absorbance Capacity (ORAC) 
method was used, which is suitable for measuring antioxidant capacities in biological 
samples. The ORAC method evaluates substances' antioxidant capacity with and without lag 
phases of their antioxidant capacities. This is especially beneficial when samples contain 
components with various slow and fast acting antioxidants. Another benefit of this method is 
that it directly estimates the chain-breaking antioxidant activity comparing to some other 
assays. 
1.7.2. Cytotoxic activity 
Cytotoxic components can induce cell death by either inducing necrosis or apoptosis. Cells 
undergoing necrosis typically undergo rapid swelling and lose membrane integrity and release 
their cytoplasmic contents (ATP, LDH etc.) into the surrounding culture medium. Cells 
undergoing rapid necrosis in vitro do not have sufficient time or energy to activate apoptosis 
process and therefore release apoptosis factors into media.  
In this study a certain amount of released ATP was measured. Advantage of measuring this 
agent is that it`s generated in only few minutes comparing to some other signalling 
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components (MTS or resazurin), which makes this assay more convenient, but also the 
probability of an interaction of the test compound with assay chemistry is reduced.  
There are numerous factors that have to be determined when choosing a cytotoxicity assay: 
type of cells used, type of control components, dose of the samples and duration of exposure. 
In this study P388 mammalian cell line was used, and curcumin and chlorambicil were the 
controls.   
 
 2. Materials and methods 
2.1. Oil distillation 
All of the samples were collected in Lismore, in July 
2009. Leaves were removed from the twigs and the oils 
were obtained using steam distillation for 48 hours. 
Samples of Plectranthus sp. ‘Hahn Tableland’ and 
ornamental Plectranthus were distilled in two batches, 
due to a large sample amount, and therefore two batches 
of oils were obtained. Molecular sieve was added to the 
first batch of P.sp. ‘Hahn Tableland’ to remove water 
from the oil, and a change of colour was observed from 
yellow to brownish-yellow. Each batch of Plectranthus 
oils was treated separately in succeeding analysis. 
 
 Figure 8. Apparatus of the steam 
water distillation 
 
Table 2.  Samples material 
Code 
Scientific 
name 
Plant material 
(g) 
Comment Weight of 
essential 
oil(g) 
Colour of 
essential oil 
P1 P. graveolens 1124.3  3.7715 Red 
P2 P. suaveolens 102.2  0.608 Orange 
P3 P. nitidus 49.8  0.2139 Red 
P4A P. sp. Hahn 
Tableland 
1st batch 4.6318 Yellow-
brownish 
P4B P. sp. Hahn 
Tableland 
2884.8 
2nd batch 4.5671 Yellow 
P6A Ornamental 
Plectranthus 
1st batch 0.6787 Yellow 
P6B Ornamental 
Plectranthus 
3600.0 
2nd batch 1.8069 Yellow 
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2.2. Phytochemistry 
2.2.1. Gas Chromatography – Mass Spectroscopy (GC-MS)  
GC-MS was used to get the information about the chemical profiles of the volatile oils, as 
well as their detailed mass spectra and retention times of individual peaks within Total Ion 
Chromatogram (TIC).  
2.2.1.1. GC-MS technical information 
The system used was Agilent 6890 with an Agilent 7673 Injector and Agilent 5973 Network 
Mass Selective Detector (MSD). The column was SGE BPX5 capillary column. Samples 
were dissolved in 100% Methanol (HPLC grade purity, purchased from LAB-SCAN) at the 
concentration of ≈10mg/mL.  
 
Method used was ELENA1 with the following parameters: 
 
Oven:       Injector (back inlet): 
Initial Temperature: 50°C   Injection volume: 1μL 
Rate: 8°C/min     Mode: Split 
Final Temperature: 300°C    Split Ratio: 50:1 
Run Time: 42.25min    Gas Type:  Helium 
 
Capillary Column – SGE BPX5:   MSD:  
Film thickness: 50.0m x 220μm x 1μm  Transfer temperature: 280°C 
Initial flow: 1.2 mL/min   Source temperature: 230°C 
Mode: constant flow    Quadrupole temperature: 150°C 
Pressure: 26.58 psi (1.83 bar)   Ionisation Voltage: 70eV 
Average velocity: 31 cm/sec   Scanning mass range: 35–350m/z 
Gas: Helium       
2.2.1.2. Identification of components 
The identification of the compounds was made by comparing the fragmentation patterns: 
1.  With reference standard (if available)   
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2.  With the ones in Database Library. Libraries used were ADAMS, WILEY275 and 
NIST 98. If the match quality was under 80%, 60%, 40% respectively, the next 
database would be scanned. 
3. With Kovats Index in the Adams book of identification of essential oils by GC-MS 
[19]. 
Reference standards used were as listed in Table 3: 
 
Table 3. Reference standards. 
Ref. Standard Supplier Purity 
p-Cymene Aldrich 99% 
(1R)-(-)-Fenchone Aldrich 98% 
Linalool Aldrich 97% 
(1R)-(+)-α-Pinene Aldrich 98% 
(S)-(-)-Limonene Aldrich 96% 
α –Bisabolol Fluka 95% 
Ocimene Fluka 97% 
Carvacrol Aldrich 98% 
± Camphor Aldrich 99% 
Thymol Aldrich 98% 
(1S)-(+)-3-Carene Aldrich 99% 
(R)-(-)-Carvone Aldrich 98% 
(1S)-(-)-Verbenene Aldrich 94% 
(-)-Carveol Aldrich 97% 
 
Standards were dissolved in methanol at the concentration of ≈ 10mg/mL. 
For all of the compounds their Kovats index (KI) was calculated. Calculation was needed 
because retention times may vary as column age or if other parameters were used and 
therefore the KI can be index based on series of references. Two standard solutions of 
different hydrocarbons were used and their accuracy in calculating the Kovats index (KI) for 
the reference substance (limonene) compared. Standard1 contained n-nonane, n-undecane, n-
hexodecane, n-eicosane and n-tetracosane. Standard2 contained n-heptane, n-octane,  n-
nonane, n-decane,  n-undecane, n-dodecane, n-tridecane, n-tetradecane, n-pentadecane, n-
hexadecane, n-heptadecane, n-octadecane, n-nonadecane, n-eicosane, n-heneicosane, n-
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docosane, n-tetracosane. Standard2 showed closer value to the one from the Adams library. 
For that reason it was used for calculating Kovats index for components found in the oil 
samples. 
In Table 4 are shown Retention times (RT-Adams) and KI (KI-Adams) from Adams Library, 
and Retention times (RT) obtained from GC-MS, as well as molecular weight (MW) of the 
component.  
 
Table 4. Hydrocarbons used in calculating KI.  
  Compound n RT MW KI-Adams RT-Adams 
KI 
calculated 
C7 n-Heptane 7 6.98 100.21 700 2.23 701 
C8 n-Octane 8 9.28 114,23 801 3.17 727 
C9 n-Nonane 9 11.65 128.2 900 4.93 792 
C10 n-Decane 10 13.94 142.29 1000 7.77 853 
C11 n-Undecane 11 16.09 156.31 1100 11.48 909 
C12 n-Dodecane 12 18.11 170.34 1200 15.77 965 
C13 n-Tridecane 13 19.99 184.365 1300 20.19 1019 
C14 n-Tetradecane 14 21.76 198.39 1389 24.10 1075 
C15 n-Pentadecane 15 23.42 212.42 1500 28.82 1130 
C16 n-Hexadecane 16 24.98 226.45 1589 32.44 1187 
C17 n-Heptadecane 17 26.45 240.48 1700 36.74 1245 
C18 n-Octadecane 18 27.84 254.51 1800 40.40 1307 
C19 n-Nonadecane 19 29.17 268.53 1900 43.92 1369 
C20 n-Eicosane 20 30.42 282.56 2000 47.33 1432 
C21 n-Heneicosane 21 31.62 269.59 2100 50.47 1502 
C22 n-Docosane 22 32.77 310.61 2200 53.54 1780 
C24 n-Tetracosane 24 35.41 338.65 2400 59.33 1798 
 
Kovats Index was calculated using the formula [19]: 
 
KI (x) = 100 Pz + [(log RT (x) – log RT (Pz)) / (log RT (Pz+1) – log RT (Pz))]  
2.2.2. Solid-Phase-Extraction (SPE)  
SPE was used to fractionate the volatile oil for further investigation. STRATA C18-E pre-
packed column with 55μm particle and 70Å pore size was used. The capacity of the column 
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was 10g and bed volume (BV) of 20 mL. The chamber used to collect the fractions was 
SUPELCO (Cat. No 5-7030) and vacuum pump was from BUCHI.  
The quality of the solvents used was HPLC purity grade from LAB-SCAN. Mili-Q water was 
obtained by water filtration using a Millipak® 40 (0.22μm pore size). Column was first 
regenerated with 2x2BV of 100% methanol and then equilibrated with 2x2BV 50% methanol. 
Elution was carried out using vacuum. Approximately 1g of oil was weighed on a Sartorius 
analytical balance and then diluted in approximately equal volume of 50% methanol and 
transferred into the column. Fractions were collected into 20mL glass vials and dried under 
nitrogen. Fractions were obtained as follows: 
 
  Mobile phase Volume BV(20ml) 
1 50% MeOH 2BV 
2 75% MeOH 4BV 
3 100% MeOH 9BV 
 
After the methanol from the fractions was evaporated further extraction was made from the 
residual water using either chloroform or hexane.  
2.2.3.    Liquid Chromatography- Mass Spectrometry (LC-MS) 
LC-MS was used to obtain additional information about mass spectra and UV-absorbance of 
components. System used was Agilent 1100 Series HPLC with binary pump, auto-injector, 
Diode Array Detector (DAD) and Mass Spectrometer Detector (MSD). DAD was equipped 
with UV and VIS lamps, and it was set to store the signals at 210, 280, 360 and 500nm 
wavelength. MSD was operating in atmospheric pressure chemical ionization (APCI) mode. 
Gas and Vaporizer temperature in the spray chamber were set at 350°C, and nebulizer 
pressure was 60 psig1 (4.14 bar). Column was Phenomenex® Luna 3 µ C18 (2) 100 Å (100 x 
4.6mm, 3 micron) with the temperature set at 40°C. Flow rate was 0.5 mL/min. Solvents were 
purchased from LAB-SCAN with HPLC purity grade. Mili-Q water was purified and filtered 
by a Millipak® 40 (0.22μm pore size). Mobile Phases were water (Solvent A) and acetonitrile 
(Solvent B), both contained 0.005% TFA (trifluoric acid) to enhance peak shape. Soniclean 
sonicator was used to homogenize and degas the solvents.  
 
                                                 
1 Pound-force per square inch gauge is a unit of pressure relative to the surrounding atmosphere.  
 33 
Method: ELENA1 
Timetable: 
Time (min) Solvent A (%) Solvent B (%) Pressure (bar) 
0.00 50 50 400 
3.00 50 50 400 
10.00 5 95 400 
18.00 5 95 400 
20.00 50 50 400 
25.00 50 50 400 
2.2.4. High Performance Liquid Chromatography (HPLC) 
2.2.4.1. Analytical HPLC 
Analytical HPLC was used to develop the chromatographic method, which was subsequently 
used in preparative HPLC. By developing the method, separation of the peaks were improved 
in order to obtain single components. 
Preparative HPLC was carried out on an Agilent 1100 system, using Phenomenex® Luna 5µ 
C18 column (5 micron packing, 150 x 4.6mm internal diameter). Column temperature was set 
at 40°C. Detector was Diode Array Detector (DAD) with UV/Vis Lamp. Signals on 210nm, 
280nm, 360nm and 560nm were stored. Mobile phases were mili-Q water (Solvent A), 100% 
methanol (Solvent B) or 95% methanol (Solvent C) in mili-Q water with 0.05% TFA. 
Timetables of different methods that were used are shown below.  
  
Method: ELENA1 
Timetable: 
Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) Pressure (bar) 
0.00 50 50 1 400 
3.00 50 50 1 400 
10.00 5 95 1 400 
18.00 5 95 1 400 
20.00 50 50 1 400 
25.00 50 50 1 400 
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Method: ELENA2 
Isocratic flow for 20min with 100% solvent (0.005&TFA/95%MeOH). 
 
Method: ELENA3 
Timetable: 
Time (min) Solvent A (%) Solvent C (%) Flow (mL/min) Pressure (bar) 
0.00 40 60 1 400 
2.00 40 60 1 400 
8.00 0 100 1 400 
18.00 0 100 1 400 
20.00 40 60 1 400 
25.00 40 60 1 400 
Method: ELENA4 
Timetable: 
Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) Pressure (bar) 
0.00 40 60 1 400 
2.00 40 60 1 400 
12.00 0 95 1 400 
20.00 0 95 1 400 
24.00 40 60 1 400 
30.00 40 60 1 400 
Method: ELENA5 
Timetable 
Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) Pressure (bar) 
0.00 50 50 1 400 
3.00 50 50 1 400 
15.00 5 95 1 400 
18.00 5 95 1 400 
20.00 50 50 1 400 
25.00 50 50 1 400 
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Figure 9.  P4A-G1 fraction run with methods ELENA1-ELENA4. 
2.2.4.2. Preparative HPLC 
Preparative HPLC was used for further fractionation of the individual fractions obtained by 
SPE.  Fractionation was carried out on a Gilson® unit equipped with Gilson® Pump 322, 
Gilson® UV/Vis-156 dual wavelength detector and FC204 fraction collector. Phenomenex® 
Luna 5μ C18 100 Å column (150 x 21.2 mm, 5 micron ) was used with a Phenomenex® 
Sepra C18 – E (50 μm particle size, 65Å) guard column. Detector signals used were 210nm 
and 280nm wavelengths. Mobile Phases were miliQ water (Solvent A) and 100% methanol 
(Solvent B) with 0.05% TFA.  
Column was first washed with isopropanol for 45 minutes, and then equilibrated with Solvent 
B for another 10 minutes with a flow rate of 15 mL/min. 
Three different methods have been used in preparative HPLC – “Elena5” to fractionate P4B-
D and P4B-C, “Elena6” for P4B-I, and “ELENA-H” for P4B-H and P3.  
Prep. HPLC method: Elena5 
From P4B-H 48 fractions were collected in 0.16min time interval and from P3 67 fractions in 
time interval of 0.24min. 
 
  
m0 5 10 15 20
mAU
0
25
50
75
100
125
150
175
 MWD1 A, Sig=210,8 Ref=off (090826\021-0201.D)
ELENA1
m0 5 10 15 20
mAU
0
20
40
60
80
100
120
 MWD1 A, Sig=210,8 Ref=off (090826\021-0501.D)
ELENA2
m0 5 10 15 20 25
mAU
0
50
100
150
200
 MWD1 A, Sig=210,8 Ref=off (090826\021-0701.D)
ELENA3
m0 5 10 15 20 25
mAU
0
50
100
150
200
 MWD1 A, Sig=210,8 Ref=off (090826A\021-0201.D)
ELENA4
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Timetable: 
Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) 
0.00 50 50 15 
15.00 40 60 15 
24.00 30 70 15 
26.00 30 70 15 
27.00 50 50 15 
HPLC method: Elena6 
Total of 47 fractions is collected in 0.17min time interval.  
Timetable: 
Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) 
0.00 40 60 15 
5.00 5 95 15 
24.00 5 95 15 
25.00 40 60 15 
HPLC method: Elena-H 
Timetable: 
Time (min) Solvent A (%) Solvent B (%) Flow (mL/min) 
0.00 25 75 15 
5.00 5 95 15 
18.00 5 95 15 
20.00 25 75 15 
From P4B-H we have collected 48 fractions in 0.16min time interval, and from P3 there were 
67 fractions in time interval of 0.24min.  
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2.2.5. Nuclear Magnetic Resonance (NMR) Spectroscopy 
Nuclear Magnetic Resonance Spectroscopy has been used to obtain structural information 
about molecules. The system was a Bruker Avance DRX-500 and TopSpin 1.8 software was 
used for results analysis. The experiments were carried out in deuterated chloroform using the 
solvent peak as a reference. The NMR spectra were recorded at 500.13 MHz for 1H and at 
125.77 MHz for 13C. The chemical shifts were expressed in parts per million (ppm) as δ 
values and the coupling constants (J) in Hertz (Hz). Multiplicities were shortened as: s 
(singlet), d(doublet), dd (doublet of doublets), m (multiplets) and br (broad).  
The structures were mainly established by three spectroscopic techniques: 
• one-dimensional spectroscopy 
•  two-dimensional homonuclear correlation spectroscopy (COSY) 
•  two-dimensional heteronuclear correlation spectroscopy: 
o HSQC (Heteronuclear Single Quantum Correlation) 
o HMBC (Heteronuclear Multiple-Bond Correlation) 
2.3.   Pharmacology 
Pharmacology assays were used to examine the essential oils and their fractions on different 
activity. The assays used were: 
? Antioxidant activity – Oxygen Radical Absorbance Capacity (ORAC) 
? Cytotoxic activity  
2.3.1. Oxygen Radical Absorbance Capacity (ORAC) 
To measure antioxidant activity of volatile oils and their fractions the Oxygen Radical 
Absorbance capacity assay was used. It directly measures the antioxidant capacity of the 
sample, using fluorescein (3’,6’-dihydroxyspiro[isobenzofuran-1[3H],9’[9H]-xanthen]-3-
one) as the fluorescent probe. Any reaction of fluorescein with peroxyl radical will be 
detected as quenching of fluorescence.  Antioxidants prevent these reactions and therefore 
preserve fluorescence. This effect is measured by assessing the area under the fluorescence 
decay curve (AUC) of the sample and compared to that of the blank. Trolox (a water soluble 
vitamin E analogue) was used as a standard to obtain a standard curve, which will be used to 
extrapolate the ORAC values from. As a positive control epicatechin, a polyphenolic 
antioxidant plant metabolite was used.   
2.3.1.1. Reagents and materials 
All samples were dissolved in methanol at the concentration of ≈10 mg/mL. 
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Phosphate buffer stock solution was prepared by dissolving 17.25g of NaH2PO4 and 86.25g of 
Na2HPO4  in 1000 mL of Milli-Q water, and pH was adjusted to 7.4. 
To prepare phosphate buffer working solution (75 mM) 100 mL of the phosphate buffer stock 
solution (750 mM) were added to 900 mL of Milli-Q water and the pH was adjusted to 7.4. 
Fluorescein stock solution (4.9 x 10-3 M) was prepared by dissolving 116 mg of fluorescein 
(C20H12O5
.2Na) in 63.2 mL of 75 mM phosphate buffer (pH 7.4). After that 5 µL of 
fluorescein stock solution (4.9 x 10-3 M) was added to 16.5 mL of the 75mM phosphate buffer 
(pH 7.4). All three solutions were stored in a fridge.  
Trolox standard stock (0.01 M) was prepared by weighing 0.25 g of Trolox and dissolving it 
in 50 mL of 75 mM phosphate buffer (pH 7.4). Volume was filled up to 100 mL with 75 mM 
phosphate buffer (pH 7.4). 
Epicatechin stock was prepared as 0.50 mg/mL solution in a phosphate buffer.  
Both solutions were stored in -20oC freezer.. 
For AAPH ([2,2’-azobis(2-amidino-propane)dihydrochloride]) working solution (20 mM) 0.2 
g of AAPH was dissolved in 25 mL of 75 mM phosphate buffer (pH 7.4). This solution was 
prepared prior to use. 
 
2.3.1.2. Procedure  
Dilutions were prepared in a clear 96-well dilution plate (JRH flat bottomed) as shown in 
Table 5. The final concentration of trolox was 0.1mM, 0.05mM, 0.025mM, 0.0125mM and 
epicatechin: 250μg/mL, 1.25μg/mL,0.625μg/mL, 0.3125μg/mL. 
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Table 5. Strategy of diluting the samples/controls used in ORAC assay 
1 2 3 4 5 6 7 8 9 10 11 12 
     conc1:     5 μL Sample + 245 μLBuffer1 / 
5 μL Trolox/Epicatechin + 995 μL  Buffer1 
+ 170 mL AAPH 
conc2:  50 μL Sample(conc1) / 100 μLTrolox/Epicatechin 
+ 100 μL Buffer2 + 170mL AAPH 
Blank: 
 
Buffer 1 
conc3:  50 μL Sample(conc2) / 100 μLTrolox/Epicatechin 
+ 100 μL Buffer2 + 170mL AAPH 
Control: 
Buffer 1 
+ 
170mL 
AAPH 
 
conc4:  50 μL Sample(conc3) / 100 μLTrolox/Epicatechin 
+ 100 μL Buffer2 + 170mL AAPH 
 
 
? Buffer1: Phosphate Buffer Working Solution (75 mM) 
? Buffer2: 10% Phosphate Buffer in Methanol  
The actual assay was conducted in a black 96-well Optiplate (Perkin Elmer). To each well 20 
μL of sample/buffer and 10 µL fluorescein was added. APPH solution (170mL) was added to 
each well, except into the blank-column (170mL phosphate buffer 75mM was added instead) 
and the fluorescence was measured.  
The chamber were the measurement was carried out was preheated to 37 oC and the plate was 
shaken 10 sec before reading. Wallac Victo 3 reader (Perkin Elmer) reads the plate 35 times a 
minute. Two replicates were done for every sample and the results represents the average 
value of both replicates of all concentration considered.  
2.3.2. Cytotoxicity 
This assay provides information about in-vitro cytotoxicity of the samples against mammalian 
cell line P388.  It is based on the fact that ATP level rapidly decreases in the cells that 
undergo necrosis or apoptosis. The light that was emitted in the reaction of ATP with D-
Luciferin in presence of firefly (Photinus pyralis) luciferase was measured.  
           
            Luciferase 
ATP + D-Luciferin + O2 -------------? Oxyluciferin  +AMP + PPi + CO2 + light 
              Mg2+ 
The light is proportional to the ATP-concentration. It was measured using the Luminescence 
ATP Detection Assay System ATPLite – PerkinElmer. 
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2.3.2.1. Reagents and materials 
Culture medium was prepared by dissolving 350mg of D-glucose (Sigma) in 86mL colour 
free DMEM (Gibco), 10 mL horse sera (Gibco), 2 mL Pen/Strep (5000 U/mL and 5000 
μg/mL)  and 2mL (Gibco) L-glutamine. All the reagents were warmed up in a Heto SBD 50 
water bath at 37°C for about 20min, mixed up in the Sterile hood and filtered using Milipore 
Stericup® and Steritop™ vacuum-driven disposable filtration system with pore size 0.22 µm.  
Cell line used was P388 purchased from American Type Culture Cell Collection. Cells were 
grown under humidified conditions with 5% CO2 at 37%. The small amount was transferred 
into the glass vial using a small transfer transfer pipette. Cells were counted in the ActDiff 
Cell Counter and diluted in a culture medium to the concentration of 0.1x106 cells/mL and 
volume of 20 mL . 
An ATPLite-PerkinElmer kit that was used for this assay contained mammalian cell lysis 
solution, substrate buffer solution, luciferase/luciferin lyophilized solution and lyophilized 
ATP standard. Chlorambucil and curcumin were used as controls and stored as a solution in 
sterilized DMSO at the concentration 60mg/mL. 
2.3.2.2. Procedure 
The whole procedure and preparation work was carried out in the Haereus Sterile hood. 
Samples were all prepared at the concentration of approximately 10 mg/mL in methanol. 
Dilutions were made in preparation plate (JRH flat bottomed plate). Controls (chlorambucil 
and curcumin) were diluted as well in following concentrations: 
 
Chlorambucil (μg/mL):       Curcumin (μg/mL):  
‐ 500     -   100 
‐ 250     -   50  
‐ 125     -   25 
‐ 62.5     -   12.5 
‐ 31.25      -   6.25 
‐ 15.625     -   3.125  
Sample/standard was transferred to the white cell culture plate in amount of 10 µL and 90 µL 
of cell dilution was added to every well. Two plates were made. Plates were incubated at 
37°C for 24 hours. The ATPLite – PerkinElmer Kit components were equilibrated to the room 
temperature. To make up a substrate solution ~ 5.2 mL of the substrate buffer solution was 
added to a vial of the lyophilised substrate solution. 
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To develop the plate, 50 μL of mammalian cell lysis solution was added to each well. The 
plate was shaken for 5 minutes on the Wallac 1296-003 
A Delfia plateshaker (700 rpm) was used to lyophilize the cells and stabilize ATP. After that 
50 μL substrate solution were added to each well and placed again on the plate shaker for 5 
minutes. Then the plate was wrapped in the aluminium foil to protect from light exposure and 
after 10 minutes the luminescence was measured using the Wallac Trilux 1450 Microbeta.  
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3. Comparison of the oil profiles  
3.1. Phytochemical comparison of the oil profiles 
Oil samples were dissolved in 100% methanol at a concentration of approximately 10mg/mL 
and profiled by GC-MS. Identification of compounds was made as described in Section 
2.2.1.2. 
3.1.1. Plectranthus graveolens (P1) 
P.graveolens oil was vibrant red coloured with a strong aromatic smell. GC-MS analysis of 
the oil showed that it contained mono-, sesqui and diterpenes. The compounds are listed in 
Table 6 and the chromatogram of the oil is shown in Figure 10. Two major components were 
found in the region of diterpenes with 21.07% and 42.83% relative distribution. Both 
components had m/z of 288. 
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Figure 10. Total Ion Chromatogram of freshly distilled oil of Plectranthus graveolens P1. 
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Table 6. Chemical profile of the Plectranthus graveolens. 
Compound 
RT 
(min) 
Area 
(%) 
MW 
(g/mol) 
KI-
Adams 
KI 
calculated Cas # 
 
Identification 
3-Octanol 14.08 1.80 129 991 1007 000589-98-0 B 
Limonene 15.12 0.88 136 1029 1057 000138-86-3 A,B 
γ-Terpinene 15.70 1.38 136 1059 1083 000099-85-3 B 
Unidentified, m/z 143 16.49 2.71 - - 1121 - - 
Fenchone 16.74 2.80 152 1086 1133 001195-79-5 A,B 
endo-Fenchyl acetate 19.09 3.47 196 1220 1253 004057-31-2 B 
β-Sesquiphellandrene 23.20 0.95 204 1522 1487 020307-83-9 B 
β-Bisabolene 24.09 1.39 204 1505 1544 000495-61-4 B 
Sesquicineole 24.35 1.26 204 1516 1560 090131-02-5 B 
β-Sesquiphellandrene 24.44 0.79 204 1522 1566 020307-83-9 B 
Sesquiabinene 
hydrate 24.93 0.81 222 1544 1597 058319-05-4 
B 
Italicene 27.05 2.31 204 1405 1744 094535-52-1 B 
ent-Primara-8,15-
diene 30.85 0.83 272  - 2036 021561-92-2 
B 
Unidentified, m/z 288 31.80 21.07 - - 2116 - - 
Unidentified, m/z 272 31.97 4.81 - - 2131 - - 
Phenantrene 32.52 1.46 270 - 2179 019407-28-4 B 
Unidentified, m/z 272 33.06 0.80 - - 2211 - - 
Unidentified, m/z 281 34.34 3.10 - - 2260 - - 
Unidentified, m/z 281 34.44 2.73 - - 2264 - - 
Unidentified, m/z 288 34.62 42.83 - - 2271 - - 
Unidentified, m/z 286 35.18 1.38 - - 2291.589 - - 
“A” - Identification has been done by comparison with the reference standard 
“B” – Identification has been done by comparison with the GC-MS database library 
3.1.2. Plectranthus suaveolens (P2) 
Only six components were detected in GC-MS in the orange oil of P. suaveolens as it is 
shown in Table 7. They included mono- and sesquiterpenes. Major compounds were β-
cedrene, 1,10-di-epi-cubenol and camphor with 51.49%, 18.22% and 20.08% relative 
distribution, respectively. The chromatogram of the oil is shown in Figure 11. 
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Figure 11. Total Ion Chromatogram of freshly distilled oil of P. suaveolens P2. 
 
 
Table 7. Chemical Profile of Plectranthus suaveolens. 
Compound 
RT 
(min) 
Area 
(%) 
MW 
(g/mol) 
KI-
Adams 
KI 
calculate
d Cas # 
 
Identification 
E-β-Ocimene 15.16 1.69 136.13 1044 1058 003779-61-1 B 
Fenchone 16.74 4.15 152.12 1083 1133 001195-79-5 A,B 
Camphor 18.17 20.08 152.12 1141 1203 000076-22-2 A,B 
γ-Cadinene 24.57 4.38 204.19 1513 1574 039029-41-9 B 
1,10-di-epi-Cubenol 26.33 18.22 222.2 1618 1692 073365-77-2 B 
β-Cedrene 26.67 51.49 204.19 1419 1716 000546-28-1 B 
“A”- Identification has been done by comparison with the reference standard 
“B” – Identification has been done by comparison with the GC-MS database library  
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3.1.3.  Plectranthus nitidus (P3) 
The oil of Plectranthus nitidus had a similar red colour to P. graveolens but not that strong 
smell. The crystallization process was observed in the vial where the oil was kept. Its GC-MS 
chromatogram showed an interesting profile since it contained only diterpenes. The 
composition of the oil is shown in Table 8 and the chromatogram in Figure 12. Major 
components had m/z of 288 with 58.74% and 14.02% relative distribution. RT (retention time) 
and molecular weight of these two compounds are the same as RT and molecular weight of 
the major compounds in P. graveolens (P1). In comparing the profiles of these two oils it can 
be seen that all diterpenes present in P1 are also present in P3. Percentages of relative 
distribution of these components followed the same pattern in both, P.graveolens and 
P.nitidus.  
10.00 15.00 20.00 25.00 30.00 35.00 40.00
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
4500000
5000000
5500000
6000000
6500000
Time-->
Abundance
TIC: P3.D\data.ms
 
Figure 12. Total Ion Chromatogram of freshly distilled oil of Plectranthus nitidus P3. 
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Table 8. Chemical Profile of Plectranthus nitidus. 
Compound 
RT 
(min) 
Area 
(%) 
MW 
(g/mol) 
KI-
Adams 
KI 
calculated Cas # 
 
Identification
Abietatriene 31.80 14.02 288 - 2116 - B 
Unidentified, m/z 272 31.97 3.30 - - 2131 - - 
8,11,13-Abietatriene 32.52 3.60 270 2056 2179 088530-52-3 B 
Unidentified, m/z 272 33.06 1.29 - - 2211 - - 
Unidentified, m/z 270 33.64 1.54 - - 2234 - - 
Unidentified, m/z 281 34.34 2.08 - - 2260 - - 
Trypethelone 34.44 7.43 272 - 2264 081750-95-0 B 
Unidentified, m/z 288 34.62 58.74 - - 2271 - - 
Unidentified, m/z 286 35.15 2.38 - - 2290 - - 
Unidentified, m/z 207 35.66 1.59 - - 2309 - - 
Unidentified, m/z 348 36.46 4.04 - - 2338 - - 
“B” – Identification has been done by comparison with the GC-MS database library 
3.1.4. Plectranthus sp. ‘Hahn Tableland’ 
3.1.4.1. First distillation batch (P4A) 
The GC-MS profile of the oil from the first distillation batch of P.sp ‘Hahn Tableland’ 
revealed only monoterpenes. The composition of this oil represented a mixture of 
monoterpene molecules with or without oxygen-containing functional groups and it is shown 
in Table 9.  Major component was δ-3-carene (42.34% relative distribution), followed by 
limonene (15.8%). Most of the compounds were isomers that had molecular weight of 134, 
136 or 150 g/mol.  Components that contained oxygen in their structure were coming out of 
the column at the end, which could be explained by their less volatile nature [6]. The 
chromatogram of the oil is shown in Figure 13. 
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Figure 13. Total Ion Chromatogram of freshly distilled oil of P. sp. ‘Hahn Tableland’ 
P4A. 
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Table 9. Chemical Profile of Plectranthus sp. ‘Hahn Tableland’ P4A. 
Compound 
RT 
(min) 
Area 
(%) 
MW 
(g/mol)
KI-
Adams
KI 
calculated Cas # 
 
Identification
α-Thujene 12.61 1.18 136 930 944 002867-05-2 B 
α-Pinene 12.95 7.44 136 939 959 000080-56-8 A,B 
Myrcene 13.87 0.83 136 990 997 000123-35-3 B 
α-Phellandrene 14.62 5.72 136 1002 1033 000099-83-2 B 
δ-3-Carene 14.70 42.34 136 1011 1037 013466-78-9 A,B 
ο-Cymene 14.87 3.25 134 1026 1045 000527-84-4 B 
Sylvestrene 14.98 1.09 136 1030 1050 001461-27-4 B 
p-Cymene 15.04 8.27 134 1026 1053 000527-84-4 A,B 
Limonene 15.13 15.80 136 1029 1057 000138-86-3 A,B 
Terpinolene 16.22 1.580 136 1088 1107 000586-62-9 B 
Linalool 16.39 1.16 154 1096 1116 000078-70-6 A,B 
Unidentified, m/z 91 18.15 2.78 - - 1202 - - 
Unidentified, m/z 94 18.33 1.19 - - 1212 - - 
Unidentified, m/z 150 18.42 2.27 - - 1217 - - 
Unidentified, m/z 150 19.36 5.09 - - 1268 - - 
“A”- Identification has been done by comparison with the reference standard 
“B” – Identification has been done by comparison with the GC-MS database library  
3.1.4.2. Second distillation batch (P4B) 
The second batch of distillation gave light yellow oil with very similar composition to the first 
batch. Monoterpenes were again the only constituents and they had very similar percentage of 
relative distribution comparing to P4A. Major component δ-3-carene is present here in 
39.08% and limonene 15.79%. The components are listed in Table 10 and chromatogram is 
shown in Figure 14.  
Some differences have been noticed between the two distillation batches. In P4A two 
components were found that were not present in P4B. They had RT 12.61 and 14.98 min and 
were identified as thymol and sylvestrene, respectively. In P4B another two components were 
found that were not present in P4A. They had RT 18.62 and 20.64 min and the latter was 
identified as carvacrol.  
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Figure 14. Total Ion Chromatogram of freshly distilled oil of P. sp. ‘Hahn Tableland’ 
P4B. 
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Table 10. Chemical profile of Plectranthus sp. ‘Hahn Tableland’ P4B. 
Compound 
RT 
(min) 
Area 
(%) 
MW 
(g/mol) 
KI-
Adams 
KI 
calculated Cas # 
 
Identification 
α-Pinene 12.95 6.78 136 939 959 000080-56-8 A,B 
Myrcene 13.87 0.74 136 990 997 000123-35-3 B 
α-Phellandrene 14.62 4.39 136 1002 1033 000099-83-2 B 
δ-3-Carene 14.69 39.08 136 1011 1037 013466-78-9 A,B 
ο-Cymene 14.87 3.45 134 1026 1045 000527-84-4 B 
p-Cymene 15.04 8.86 134 1026 1053 000527-84-4 A,B 
Limonene 15.13 15.79 136 1029 1057 000138-86-3 A,B 
Terpinelone 16.22 1.42 136 1088 1107 000586-62-9 B 
Linalool 16.39 1.16 154 1096 1116 000078-70-6 A,B 
Unidentified, m/z 91 18.15 3.74 - - 1202 - - 
Unidentified, m/z 94 18.33 1.42 - - 1212 - - 
Unidentified, m/z 150 18.42 3.67 - - 1217 - - 
Unidentified, m/z 150 18.62 1.92 - - 1228 - - 
Unidentified, m/z 150 19.36 6.18 - - 1268 - 
- 
Carvacrol 20.64 1.41 150 1299 1338 000499-75-2 A,B 
“A”- Identification has been done by comparison with the reference standard 
“B” – Identification has been done by comparison with the GC-MS database library 
3.1.5. Ornamental Plectranthus  
3.1.5.1. First distillation batch (P6A) 
Ornamental Plectranthus oil had a light yellow colour, similar to one of P4B. Its chemical 
profile is shown in Table 11 and it contained mono- and sesquiterpenes. Major components 
were monoterpenes δ-3-carene, camphor and carvacrol with 20.68%, 12.46% and 23.47% 
relative distribution. All sesquiterpenes were isomers with MW (molecular weight) 204 
g/mol, except trans-calamene that had MW 202 g/mol. The chromatogram is shown in Figure 
15.  
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Figure 15. Total Ion Chromatogram of freshly distilled oil of ornamental Plectranthus. 
 
Table 11. Chemical Profile of ornamental Plectranthus P6A.  
Compound 
RT 
(min) 
Area 
(%) 
MW 
(g/mol) 
KI-
Adams 
KI 
calculated Cas # 
 
Identification
Myrcene 13.87 0.76 136 990 197 000123-35-3 B 
δ-3-Carene 14.69 20.68 136 1011 1037 013466-78-9 A,B 
δ-2-Carene 14.82 3.75 136 1002 1043 000554-61-0 B 
p-Cymene 15.04 6.39 134 1026 1053 000527-84-4 A,B 
Limonene 15.13 1.09 136 1029 1057 000138-86-3 A,B 
γ-Terpinene 15.70 7.23 136 1059 1083 000099-85-4 B 
Camphor 18.17 12.46 152 1146 1203 000076-22-2 A,B 
Carvacrol, 
methylether 19.34 0.75 164 1244 1267 006379-73-3 
B 
Carvacrol 20.64 23.47 150 1299 1338 000499-75-2 A,B 
α-Copaene 22.19 1.67 204 1376 1427 003856-25-5 B 
α-cis-Bergamotene 22.93 5.12 204 1412 1471 018252-46-5 B 
Z-Caryophyllene 23.17 5.62 204 1408 1485 000118-65-0 B 
α-Humulene 23.79 1.57 204 1454 1521 006753-98-6 B 
α-Guaiene 24.38 5.56 204 1439 1555 003691-12-1 B 
α-Selinene 24.43 0.81 204 1498 1557 000473-13-2 B 
δ-Amorphene 24.51 1.93 204 1512 1562 189165-79-5 B 
Unidentified, m/z 202 28.12 1.14 - - 1821 - - 
“A”- Identification has been done by comparison with the reference standard 
“B” – Identification has been done by comparison with the GC-MS database library 
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3.1.5.2. Second distillation batch (P6B)  
The oil from the second distillation batch, P6B, had very similar profile to P6A. The 
compounds are listed in Table 12 and chromatogram is shown in Figure 16. Myrcene was the 
only component detected in P6A that was not in P6B and its distribution was only 0.76%. 
Also some differences in percentages of relative distribution of the main components were 
present. Carvacrol had relative distribution of 29.33% in P6B and 23.47% in P6A. On the 
other hand, δ-3-carene was in smaller amount (15.57%) in P6B compared to P6A (20.68%).  
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Figure 16. Total Ion Chromatogram of freshly distilled oil of ornamental Plectranthus. 
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Table 12. Chemical Profile of ornamental Plectranthus P6B. 
Compound 
RT 
(min) 
Area 
(%) 
MW 
(g/mol)
KI-
Adams 
KI 
calculated Cas # 
 
Identification
δ-3-Carene 14.69 15.57 136 1011 1037 013466-78-9 A,B 
δ-2-Carene 14.82 3.60 136 1002 1043 000554-61-0 B 
p-Cymene 15.04 5.57 134 1026 1053 000527-84-4 A,B 
Limonene 15.12 0.89 136 1029 1057 000138-86-3 A,B 
γ-Terpinene 15.70 6.43 136 1059 1083 000099-85-4 B 
Camphor 18.17 14.49 152 1146 1203 000076-22-2 A,B 
Carvacrol, 
methylether 19.34 0.76 164 1244 1267 006379-73-3 
B 
Carvacrol 20.65 29.33 110 1299 1338 000499-75-2 A,B 
α-Copaene 22.19 1.55 204 1376 1427 003856-25-5 B 
α-cis-Bergamotene 22.93 4.84 204 1412 1471 018252-46-5 B 
E-Caryophyllene 23.17 5.82 204 1419 1485 000087-44-5 B 
α-Humulene 23.79 1.67 204 1454 1521 006753-98-6 B 
β-Selinene 24.38 5.73 204 1490 1555 017066-67-0 B 
α-Selinene 24.43 0.79 204 1498 1557 000473-13-2 B 
δ-Amorphene 24.51 1.79 204 1512 1562 189165-79-5 B 
Unidentified, m/z 202 28.12 1.18 - - 1821 - - 
“A”- Identification has been done by comparison with the reference standard 
“B” – Identification has been done by comparison with the GC-MS database library 
3.1.5.3. Comparison of the P6A and P6B after three months period 
During this study oils were kept in the closed glass vials in the laboratory. They were thus 
exposed to the daylight and room temperature. After three months a change in colour between 
the two oils was observed. P6A was still yellowish but became a fraction turbid and P6B was 
light greenish coloured. GC-MS analysis was done to see if the composition has changed. The 
results are listed in Table 13. 
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Table 13. Chemical composition of P6A, P6B and change in percentage of distribution. 
P6A P6B 
Compound RT(min) Area2 (%) 
Area1-
Area2 (%) Area2 (%) 
Area1-
Area2 (%) 
δ-3-Carene 14.68 16.57 4.11 13.82 1.75 
o-Cymene 14.85 1.27 New 1.01 New 
p-Cymene 15.03 15.00 -8.61 11.34 -5.77 
γ-Terpinene 15.70 7.23 0 2.35 4.08 
Camphor 18.16 12.97 0.51 14.68 -0.19 
Carvacrol 20.64 20.23 3.24 20.80 8.53 
α-Copaene 22.17 1.56 0.11 1.60 -0.05 
α-cis-
Bergamotene 22.91 4.60 0.52 4.72 0.12 
E-Caryophyllene 23.14 1.57 4.05 3.47 0.59 
β-Selinene 24.36 5.68 0.12 6.07 -0.34 
δ-Amorphene 24.48 1.61 0.81 1.75 0.04 
Caryophyllene 
oxide 26.01 3.15 New 2.07 New 
Unidentified, m/z 
202 28.10 1.11 0.03 1.19 -0.01 
 
The last column in Table 13 is showing difference in percentage of distribution between the 
fresh oil (Area1) and the one stored for three months (Area2). The relative distribution of 
some components has significantly changed, and two new components had been identified. 
The percentage of relative distribution of δ-3-carene has dropped 20% in P6A, whereas in 
P6B has not changed a lot. On the other hand carvacrol has degraded more in P6B (decrease 
by over 20%) compared to P6A (approximately 13%). The component that drastically 
changed its amount is p-cymene with about 100% increase in both of the oils. New 
components that have been detected are caryophyllene oxide and o-cymene. The first is 
probably the oxidation product of E-caryophyllene, since decrease of its amount was 
approximately the same as increase of E-caryophyllene oxide.  
The non-stable nature of monoterpenes has been reported. Tammela et al. have reported 
decreasing in δ-3-carene and α-pinene content of ageing pine seeds [20].  
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The presence of two rings in structure of both compounds probably contributed to their 
instability. An increased content of o- and p-cymene suggests possible degradation of δ-3-
carene and α-pinene to o- and p-cymene. This leads to the conclusion that some monoterpenes 
were unstable and therefore should be kept very carefully, in the tightly sealed vials, and not 
exposed to any source of free energy like light or temperature.      
3.2. Pharmacology of the Plectranthus oils 
3.2.1. ORAC 
Samples were dissolved in 100% methanol in approximate concentration of 10mg/mL. The 
results of the ORAC assay are listed inTable 14. P6A and P6B had the highest antioxidant 
activity, followed by P3 and P4B. The high activity of ornamental Plectranthus is probably 
due to its high percentage of carvacrol that has already been reported as highly antioxidant 
[21]. Interestingly P6B showed noticeably higher value compared to P6A, which is again 
probably due to the higher relative distribution of carvacrol (29.33%, Table 12). There was a 
significant difference between P4A and P4B values, but there was no significant difference 
observed between the GC-MS profiles of P4A and P4B (Figure 17). However there is a 
possibility that some oxidation process happened after adding molecular sieve to the first oil 
batch which resulted in smaller antioxidant activity. 
Table 14. ORAC values of Plectranthus oils. 
Sample ORAC value (μmol TE/g)  RSD (%) 
P1 584 ± 52 9.01
P2 699 ± 54 7.69
P3 1351± 362 26.79
P4A 531.358 ± 89 4 16.80
P4B 1111 ± 168 15.15
P6A 1560 ± 356 22.84
P6B 2215 ± 377 17.00
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 Figure 17.  Overlaid TIC of P4A and P4B. 
3.2.2. Cytotoxicity assay 
Cytotoxic activity against P388 mammalian cell line was represented as IC50 value and shown 
in Figure 18. P3 had the highest cytotoxic activity, followed by P1 and P2. Low IC50 value 
can be contributed to the presence of diterpenes in P3, since they are the components in this 
oil and the major components in P1. Cytotoxic activity of diterpenes in this genus has already 
been reported. Forskolin, a diterpene from Indian plant Coleus forskohlii (synonym for 
Plectranthus barbatus) has reduced tumour colonization in the lungs [16]. Another diterpene 
in the same plant was found to be highly active against breast and uterine cell lines [22].  The 
fact that P3 was much more active than P1 is probably because it contained only diterpenes 
whereas P1 oil had other terpenes. Detailed cytotoxic results are listed in Appendix 1.  
 
Figure 18.  IC50 (μmol/mL) values of Plectranthus volatile oils (P1-P6).
P4A 
P4B 
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4. Plectranthus sp. ‘Hahn Tableland’: P4B 
4.1.  Fractionation 
P4B oil was fractionated using SPE column as described in Chapter 2.2.2. Four batches of 
fractionations of 1g each have been carried out and fractions were collected as shown in Table 
15 and fractionation was done as is shown in Figure 19.  
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48 
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Figure 19.  Schematic representation of the fractionation of P4B. 
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Table 15. SPE fractionation strategy and yields of the individual fractions (batches I, II, 
III and IV). 
    Batch I Batch II Batch III Batch IV 
Crude 
Oil (g)   0.9313 0.9513 0.9545 0.9700 
Fraction 
Code 
Mobile 
Phase, 
MeOH in 
H2O (%) 
Weight  
(g) 
Yield 
(%) 
Weight 
(g) 
Yield 
(%) 
Weight 
(g) 
Yield 
(%) 
Weight  
(g) 
Yield
(%) 
B 50 0.0018 0.19 0.0028 0.29 0.012 1.26 0.001 0.10 
C 75 0.0694 7.45 0.0782 8.22 0.1844 19.32 0.0934 9.63 
D 75 0.1467 15.75 0.1693 17.80 0.0725 7.60 0.0858 8.85 
E 75 0.0119 1.28 0.0141 1.48 0.0042 0.44 0.0044 0.45 
F 75 0.0096 1.03 0.025 2.63 0.0036 0.38 0.0033 0.34 
G 100 0.0174 1.87 0.0334 3.51 0.0043 0.45 0.014 1.44 
H 100 0.0205 2.20 0.0293 3.08 0.039 4.09 0.0411 4.24 
I 100 0.0254 2.73 0.0211 2.22 0.0186 1.95 0.0198 2.04 
J 100 0.003 0.32 0.0038 0.40 0.0018 0.19 0.0023 0.24 
K 100 0.0056 0.60 0.005 0.53 0.0121 1.27 0.0231 2.38 
L 100 0.1994 21.41 0.4956 0.00 0.1828 19.15 0.0969 9.99 
M 100 0.3912 42.01 0.2199 23.12 0.0226 2.37 0 0.00 
    
Fractions B, C, D, E, F, and G were extracted with chloroform and I, J and K with hexane. No 
extraction was made for fractions L and M. The extracts were concentrated to dryness under 
nitrogen and dissolved in 100% methanol for further analysis. GC-MS and LCMS profiling 
was done for all of the fractions and after analysis, fractions that were labelled with the same 
letter from all four groups had been combined. Fractions J and K were combined together and 
L and M were combined resulting to 10 pooled fractions.    
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4.2.  GC-MS and LCMS analysis of the fractions 
4.2.1. P4B-B fraction 
Fraction P4B-B showed no response in GC-MS analysis, but from LCMS profile one large 
peak was observed at the RT of 2.6 min with m/z 201.1 (Figure 20).   
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Figure 20. UV spectra at 210, 280, 360 and 500nm wavelength and LCMS profile of 
P4B-B fraction. 
4.2.2. P4B-C fraction 
GC-MS analysis of fraction P4B-C showed one large peak at 19.35 min (Figure 21) and the 
composition was determined by comparison with database. Compounds found in the P4B-C 
fraction are listed in Table 16. The major component of fraction C at 19.35 min was 
chrysanthenone (41.69% relative distribution). Other components were p-cymen-8-ol (27.55% 
relative distribution) and 3-caren-2-one (10.29%), which was not observed in the crude oil 
and could be an oxidized product of δ-3-carene.  
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UV 500nm 
APCI MS(+) mode 
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Figure 21.  Total ion chromatogram of the P4B-C fraction. 
 
Table 16. Chemical composition of the P4B-C fraction.  
Compound 
RT 
(min) 
Area 
(%) 
Match 
(%) 
KI-
calculated 
KI 
Adams Cas # 
Unidentified, m/z 119 18.14 4.44 42 1202 - - 
p-Cymen-8-ol 18.42 27.55 87 1217 1182 1197-01-9 
Unidentified, m/z 150 18.56 1.53 78 1225 - - 
Unidentified, m/z 150 18.62 8.07 68 1202 - - 
Chrysanthenone 19.35 41.69 83 1267 1127 473-06-3 
Eucarvone 19.43 2.36 94 1271 1150 503-93-5 
3-Caren-2-one 20.02 10.29 95 1320 1248 53585-45-8 
Unidentified, m/z 150 21.29 3.80 86 1374 - - 
4.2.3. P4B-D fraction 
P4B-D fraction showed the most complex profile (Figure 22) with 21 components that are 
summarized in Table 17. Numerous compounds could not be identified by comparison with 
library database. The major components of this fraction had RT of 18.14 and 19.34 min with 
m/z 119 and 150, respectively. The latter (RT 19.34 min) was also observed as the major 
component in the P4B-C fraction. The components that could be identified with library 
database were linalool (4.76% relative distribution), p-cymen-8-ol (3.19% relative 
distribution), trans-carveol (5.75% relative distribution), eucarvone (2.89% relative 
distribution), carvone (6.22% relative distribution), thymol (4.89% relative distribution), 
carvacrol (12.40% relative distribution) and 2-caren-4-one (3.89% relative distribution).  
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Figure 22. Total ion chromatogram of the P4B-D fraction. 
 62 
 
Table 17. Chemical composition of the P4B-D fraction. 
Compound 
RT 
(min) 
Area 
(%) 
Match 
(%) 
KI-
calculated 
KI 
Adams Cas # 
Linalool 16.37 4.76 96 1115 1096 78-70-6 
Unidentified, m/z 119 18.14 16.39 59 1202 1166 1686-2--0 
Unidentified, m/z 91 18.32 6.74 64 1212 - - 
Unidentified, m/z 150 18.41 6.15 83 1217 - - 
Unidentified, m/z 148 18.55 2.94 46 1224 - - 
p-Cymen-8-ol 18.61 3.19 87 1228 1182 1197-01-9 
Unidentified, m/z 136 18.80 2.19 64 1238 - - 
Unidentified, m/z 164 18.92 1.56 50 1244 - - 
Unidentified, m/z 152 19.07 1.16 46 1252 - - 
Unidentified, m/z 148 19.13 1.72 70 1255 - - 
trans-Carveol 19.23 5.75 86 1261 1216  99-48-9 
Unidentified, m/z 150 19.34 12.41 78 1267 - - 
Eucarvone 19.42 2.89 86 1271 1150 503-93-5 
Unidentified, m/z  19.51 1.43 60 1275 - - 
Carvone 19.85 6.22 89 1293 1243  99-49-0 
Unidentified, m/z 165 20.33 0.70 38 1320 - - 
Unidentified, m/z 150 20.39 0.91 76 1323 - - 
Thymol 20.49 4.89 90 1329 1290  89-83-8 
Carvacrol 20.62 12.40 93 1337 1299 499-75-2 
Unidentified, m/z 167 20.75 0.78 50 1344 - - 
2-Caren-4-one 21.95 3.89 83 1412 - - 
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4.2.4. P4B-E fraction 
The TIC of P4B-E is shown in Figure 23. The database showed carvacrol (32.66% relative 
distribution) as the major component in P4B-E, followed by Z-ethyl cinnamate (12.24% 
relative distribution) and an unknown component with RT 20.48 min (14.79% relative 
distribution). This fraction showed an interesting profile because all of the compounds had 
RT>20min, which was the part of chromatogram that has not been observed in the profile of 
the crude oil. This suggests a low proportion of these compounds in the oil. However, no 
further fractionation was carried out because of the low yield. Composition of the fraction is 
shown in Table 18.  
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Figure 23. Total ion chromatogram of the P4B-E fraction. 
 
Table 18. Chemical composition of the P4B-E fraction. 
Compound 
RT 
(min) 
AREA 
(%) 
Match 
(%) 
KI-
calculated KI Adams Cas # 
Thymol 20.38 6.45 93 1323 1290  89-83-8 
Unidentified, m/z 150 20.48 14.79 90 1329 - - 
Carvacrol 20.61 32.66 95 1336 1299 499-75-2 
Unidentified, m/z 163 21.73 7.75 22 1399 - - 
Unidentified, m/z 159 22.22 12.80 38 1429 - - 
Unidentified, m/z 153 23.52 6.65 38 1507 - - 
Z-Ethyl cinnamate 23.74 12.24 97 1521 1377 4610-69-9 
Unidentified, m/z 281 32.98 6.66 50 2209 - - 
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4.2.5. P4B-F fraction 
The GC-MS profile of fraction F showed two sesquiterpenes in approximately the same 
amount (Figure24). They were identified as spathulenol and intermedeol by comparison with 
the database.  
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Figure 24. Total ion chromatogram of the P4B-F fraction. 
 
Table 19. Chemical composition of the P4B-F fraction. 
Compound 
RT 
(min) 
AREA 
(%) 
Match 
(%) 
KI-
calculated 
KI 
Adams Cas # 
Spathulenol 25.84 49.65 99 1659 1578 6750-60-3 
Intermedeol 27.36 50.35 97 1766 1666 6168-59-8 
4.2.6. P4B-G fraction 
The chromatogram of the fraction P4B-G is shown in Figure 25. Fraction P4B-G contained 
spathulenol and intermedeol, but also two other unidentified components with RT of 24.88 
and 27.05 min. The compounds found in the fraction are listed in Table 20.  
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Figure 25. Total ion chromatogram of the P4B-G fraction. 
Table 20. Chemical composition of the P4B-G fraction. 
Compound 
RT 
(min) 
AREA 
(%) 
Match 
(%) KI-calculated KI Adams Cas # 
Unidentified, m/z 147 24.88 8.95 47  1594 - - 
Spathulenol 25.85 29.6 95 1655 1578 6750-60-3 
Unidentified, m/z 207 27.05 9.60 72 1744 - - 
Intermedeol 27.38 36.37 97 1767 1666 6168-59-8 
4.2.7. P4B-H fraction 
The chromatogram of the P4B-H fraction is shown in Figure 26. Spathulenol and intermedeol 
were also present in high percentage in this fraction, as well as o-cymene and unidentified 
component with RT 24.88 min. During SPE fractionation this fraction was collected as a 
yellow-orange band. Composition of the fraction is shown in Table 21.  
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Figure 26. Total ion chromatogram of the P4B-H fraction. 
Table 21. Chemical composition of the P4B-H fraction. 
Compound 
RT 
(min) Area (%) 
Match 
(%) 
KI-
calculated KI Adams Cas # 
o-cymene 15.02 24.87 90 1052 1026 527-84-4 
Limonene 15.11 10.53 81 1056 1029 138-86-3 
Unidentified, m/z 147 24.88 29.35  47 1594 - - 
Spathulenol  25.85 17.27 96 1655 1578 6750-60-3 
Intermedeol 27.38 28.50 83 1767 1666 6168-59-8 
4.2.8. P4B-I fraction 
P4B-I contained δ-3-carene and limonene as major components, which are also the main 
components in the crude oil. Components are listed in Table 22 and the chromatogram of the 
fraction is shown in Figure 27. The major component of the oil, δ-3-carene, was only found in 
this fraction. Considering the fact that fraction I had relative low yield (<3% in all four 
fractions) and the non-stabile nature of δ-3-carene it was thought that this compound must 
have decomposed during the fractionation process.     
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Figure 27. Total ion chromatogram of the P4B-I fraction. 
Table 22. Chemical composition of the P4B-I fraction. 
Compound RT 
AREA 
% 
Match 
% KI-calculated 
KI 
Adams Cas # 
α-Phellandrene 14.61 6.03 83 1033 1002 99-83-2 
δ-3-Carene 14.68 39.48 94 1036 1011 13466-78-9 
o-Cymene 14.86 3.60 90 1045 1026 527-84-4 
Limonene 15.12 34.65 91 1056 1029 138-86-3 
Terpinolene 16.21 3.41 87 1106 1088 586-62-9 
4.2.9. P4B-J and P4B-K fractions 
GC-MS profile from the fractions P4B-J and P4B-K (Figure 28) showed a sesquiterpene, β-
selinene, as the major compound (Table 23). Other minor peaks were also present in this 
fraction, but they were not integrated due to the low proportion. 
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Figure 28. Total ion chromatogram of the P4B-J and P4B-K fractions. 
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Table 23. Chemical composition of the P4B-J and P4B-K fractions. 
Compound 
RT 
(min) 
AREA 
(%) 
Match 
(%) KI-calculated KI Adams Cas # 
β-Selinene 24.20 100.00 81 1551 1490 17066-67-0 
4.2.10. P4B-L and P4B-M fractions 
Similar to the P4B-B, fractions L and M did not show any response in the GC-MS, but the 
LCMS profile (Figure 29) showed two components with the same fragmentation pattern of 
m/z of 230.  
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Figure 29. UV spectra at 210, 280, 360 and 500nm wavelength and LCMS profile of 
P4B-K and P4B-M fractions. 
4.3. Pharmacology of the P4B subfractions 
4.3.1. ORAC 
The results of the ORAC assay on the P4B fractions are summarized in Table 24. Fraction D 
had the highest antioxidant activity with ORAC value of 2368 μmol TE/g, which is much 
higher than any activity found in the crude oil. The reason could be due to the presence of 
carvacrol. Fraction E showed also a high activity which could be explained by the high 
amount of carvacrol and thymol, that were already reported to have high antioxidant activity 
[23]. 
UV 210nm 
UV 280nm 
UV 360nm 
UV 500nm
APCI MS (+) mode
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Table 24. ORAC results of the P4B fractions. 
Sample ORAC value (μmol TE/g) RSD (%) 
P4B-B 72 ± 25 34.80 
P4B-C 989 ± 91 9.19 
P4B-D 2368 ± 100 8.41 
P4B-E 1600.65 ± 181 11.31 
P4B-F 642 ± 80 12.42 
P4B-G 562 ± 69 12.37 
P4B-H 546 ± 130 23.84 
P4B-I 593 ± 191 32.25 
P4B-K 335 ± 107 31.91 
P4B-M 101 ± 20 19.49 
4.3.2. Cytotoxicity assay 
The results of the cytotoxic assay are shown in Figure 30. Fractions E, F and G showed the 
highest activity with IC50 36, 29 and 38 μmol/mL, respectively. Carvacrol and thymol, which 
were the major components in fraction E have been reported to have cytotoxic properties [24]. 
Fractions F and G contained spathulenol and intermedeol as major components, and 
intermedeol is already reported as cytotoxic [25]. Cytotoxic effects of monoterpenes in 
general have also been reported  and their use as possible future anti-cancer drugs [26]. 
Fractions B, J+K and L+M did not show any activity against P388 cell line. Detailed 
cytotoxic results are listed in Appendix 1. 
   
Figure 30. IC50 (μmol/mL) values of the P4B-D fractions. 
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4.4. Preparative HPLC 
The fractions C, D, H and I were further fractionated by preparative HPLC. Fraction D 
showed highest antioxidant activity, whereas fraction C had interesting chemical profile 
containing 3-caren-2-one, the possible oxidation product of the major component from the 
crude oil. Fraction H was collected as a band from SPE column, and contained intermedeol 
and spathulenol, sesquiterpenes that are possibly responsible for cytotoxic activity of the 
fractions F, G and H. Fractions E and F showed high cytotoxic activity but were not 
fractionated further because of lack of material. Fractionations have been carried out by the 
preparative HPLC using the methods described in the Chapter 2.2.4.2.   
4.4.1. Fraction P4B-C 
The chromatogram of the P4B-C fraction, showing spectra of 210 and 280 nm and solvent 
gradient of the mobile phases, is shown in Figure 31 Figure 31. From the total of 48 fractions 
17 were dried under nitrogen and extracted with chloroform. Altogether 300mg of P4B-C 
were fractionated and the yields of the obtained fractions are shown in Table 25. After 
extraction a GC-MS analysis was done. Detailed data on composition of each fraction are 
shown in Appendix 2. Pure fractions were subjected to NMR analysis.   
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Figure 31. Prep. HPLC Chromatogram of the P4B-C fraction (Method: ELENA5). 
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Table 25. Yields of the P4B-C fractions.  
 Fraction Weight (g) Yield (%) 
FR.7 0.0027 0.90 
FR.8 0.0035 1.17 
FR.11 0.0023 0.77 
FR.14 0.0089 2.97 
FR.15 0.0050 1.67 
FR.16 0.0046 1.53 
FR.18 0.0270 9.00 
FR.19 0.0260 8.67 
FR.20 0.0100 3.33 
FR.21 0.0090 3.00 
FR.22 0.0032 1.07 
FR.23 0.0032 1.07 
FR.24 0.0015 0.50 
FR.27 0.0026 0.87 
FR.28 0.0026 0.87 
FR.32 0.0049 1.63 
FR.37 0.0140 4.67 
4.4.1.1. Identification of P4B-C-14 as 3-caren-2-one 
The 1H and 13C NMR data of the fraction P4B-C-14 are shown in Table 26 and the compound 
was elucidated as 3-caren-2-one with molecular formula C10H14O and molecular weight of 
150.22 g/mol, which agrees with m/z of 150 g/mol found in GC-MS (Figure 33). RT was 
20.02 min. The structure is shown in Figure 32. This compound was not found in the crude oil 
and it is possibly the oxidation product of the δ-3-carene, the major component from the oil, 
since δ-3-carene can be easily oxidized [27]. 
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Figure 32.  Structure of P4B-C-14 (3-caren-2-one, CAS Registry Number: 53585-45-8). 
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Figure 33. GC-MS profile of the fraction P4B-C-14. 
Table 26.  The 1H and 13C NMR data for P4B-C-14 (3-caren-2-one). 
Chemical Shift, ppm 
Position 
1H 13C 
1 - 135.3 
2 - 196.8 
3 1.64  dd  (1.6, 7.85) 34.6 
4 1.43  t  (8.1/8.0) 26.6 
5 2.70   
 2.45  dt  (1.75) 
23.3 
6 6.40  m 142.7 
7 - 22.1 
8 1.08  s 14.5 
9 1.19  s 28.7 
10 1.76 16.3 
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4.4.1.2. Identification of P4B-C-18 as m-cymen-8-ol 
The 1H and 13C NMR data of the fraction P4B-C-18 are shown in Table 27. The compound 
was identified as m-cymen-8-ol with molecular formula C10H14O and molecular weight of 
150.22 g/mol which corresponds with m/z of 150 from GC-MS profile (Figure 35). The 
structure is shown in Figure 34. This compound has been already found in Artemisia pontica 
[28] but has not been reported in Plectranthus genus before.  
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Figure 34. Structure of P4B-C-18 (m-cymen-8-ol, CAS registry number: 5208-37-7). 
50 100 150 200 250 300 350 400 450 500 550
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
m/z-->
Abundance
Scan 2335 (18.424 min): P4B-C-18.D\data.ms
135
91
65
113 207 281 325165 415251 489355 393 446 547302 513
 
Figure 35. GC-MS profile of the P4B-C-18 fraction. 
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Table 27. 1H and 13C NMR data for P4B-C-18 (m-cymen-8-ol) 
Chemical Shift, ppm 
Position 
1H 13C 
1 - 149.3 
2 7.32  br s 125.3 
3 - 138.0 
4 7.06  br d  (7.25) 127.6 
5 7.23  t  (7.5, 7.65) 128.3 
6 7.28  br d  (8.0, 9.4) 121.6 
1` 1.58  s 32.0 
2` - 72.7 
3-CH3 2.37  s 21.8 
 
4.4.2. Fraction P4B-D 
The chromatogram of the P4B-D fraction is shown in Figure 36. From the total of 58 fractions 
collected, 14 were dried under nitrogen, extracted with chloroform and analysed in GC-MS. 
Yields of the fractions are shown in Table 28. Detailed data on composition of each fraction 
are shown in Appendix 2. Pure fractions were subjected to NMR analysis.  
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Figure 36. HPLC Chromatogram of the P4B-D fraction (Method: ELENA5). 
Table 28. Yields of P4B-D subfractions. 
Fraction  Weight (g) Yield (%) 
FR.8 0.0151 4.08 
FR.9 0.0088 2.38 
FR.13 0.016 4.32 
FR.14 0.0162 4.38 
FR.15 0.015 4.05 
FR.16 0.0192 5.19 
FR.19 0.0124 3.35 
FR.20 0.0137 3.70 
FR.21 0.0116 3.14 
FR.22 0.0068 1.84 
FR.25 0.0113 3.05 
FR.26 0.009 2.43 
FR.27 0.0083 2.24 
FR.28 0.0087 2.35 
4.4.2.1. Identification of P4B-D-8 as 3,6,6-trimethyl-2,4-cycloheptadien-1-
one 
The compound was isolated from the fractions P4B-D-8 and P4B-C-18 and elucidated as 
3,6,6-trimethyl-2,4-cycloheptadien-1-one with molecular formula C10H14O and molecular 
weight of 150.22g/mol. The structure is shown in Figure 37 and the 1H and 13C NMR data in 
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Table 29. The compound has not been reported in this genus before but it was already isolated 
from the oxidised oil of Piper nigrum. 
Since the fractions P4B-D-8 and P4B-C-18 were not pure and there was no component with 
the same RT in either of them, it was not possible to define the RT time of this component or 
to explain this finding. 
To the knowledge of the author of this thesis no activity was reported for this compound. 
Thus, eucarvone (2,6,6-trimethyl-2,4-cycloheptadien-1-one), a compound with very similar 
structure, has been reported to have very high insecticidal activity which could also be a 
property of 3,6,6-trimethyl-2,4-cycloheptadien-1-one [29]. 
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Figure 37. Structure of P4B-D-8 (3,6,6-Trimethyl-2,4-cycloheptadien-1-one, CAS 
Registry Number: 2767-18-2). 
 
Table 29. 1H and 13C NMR data for P4B-D-8 (3,6,6-trimethyl-2,4-cycloheptadien-1-
one). 
Chemical Shift, ppm 
Position 
1H 13C 
1 - 199.7 
2 6.04  d  (1.3) 129.8 
3 - 147.8 
4 5.75  dd  (1.4, 11.85) 126.7 
5 6.07  d  (1.85) 150.1 
6 - 32.9 
7 2.60  s 54.1 
3-CH3 2.01  d  (1.3) 27.4 
6- CH3 1.11  s 27.1 
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4.4.2.2.  Identification of P4B-D-14 as 5-isopropenyl-2-methyl-2-
cyclohexen-1-one (Carvone) 
The 1H and 13C NMR data of the fraction P4B-D-14 are shown in Table 31 and the structure 
in Figure 38. The compound was elucidated as 5-isopropenyl-2-methyl-2-cyclohexen-1-one 
with molecular formula C10H14O and molecular weight of 150.22 g/mol which corresponds to 
m/z of 150 from GC-MS profile (Figure 39). 
Carvone has been reported as carminative agent [30], and also as antibacterial and antifungal 
[31].  
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Figure 38. Structure of the P4B-D-14 (5-isopropenyl-2-methyl-2-cyclohexen-1-one, CAS 
Registry Number: 99-49-0). 
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Figure 39. GC-MS profile of the fraction P4B-D-14. 
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Table 30. 1H and 13C NMR data for P4B-D-14 (5-isopropenyl-2-methyl-2-cyclohexen-1-
one). 
Chemical Shift, ppm 
Literature value 
[32] Position 
1H 13C 13C 
1 - 200.0 198.4  s  (0.608) 
2 - 135.7 135.4  s  (0.625) 
3 6.75 144.8 144.0  d  (0.828) 
4 2.45  m 
2.335  dd  (13.3, 16) 
31.5 31.4  t  (1.0) 
5 2.69  m 42.7 42.7  d  (0.739) 
6 2.59  ddd  (1.55, 3.75, 
16.0) 
2.35  dd  (13.3, 16.0) 
43.4 43.2  t  (0.769) 
1’ 1.76 br s 20.7 20.5  q  (0.98) 
2’ - 146.9 146.8  s  (0.576) 
3’ 4.81  t  (1.15, 1.1) 
4.76  br s 
110.7 110.5  t  (0.874) 
 
4.4.2.3.  Identification of P4B-D-25 and P4B-D-27 as 5-isopropyl-2-
methylphenol (Carvacrol) 
The 1H and 13C NMR data are shown in Table 32 and the compound was elucidated as 5-
isopropyl-2-methylphenol. Structure is shown in Figure 40 and GC-MS profile in Figure 41. 
The compound had RT 20.64 min, a molecular formula C10H14O and molecular weight 150.22 
g/mol, which corresponds to m/z from GC-MS profile. Both P4B-D-25 and P4B-D-27 
fractions had relative high ORAC values. The fraction P4B-D-25 had a value of 4480 μmol 
TE/g and P4B-D-27 value of 6959 μmol TE/g. The two fractions were only relatively pure 
which explains different antioxidant activity. Carvacrol has already been reported to have a 
high antioxidant activity, and this is probably due to its phenolic structure [21].  
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Figure 40. Structure of the P4B-D-25 (5-isopropyl-2-methylphenol,CAS Registry 
Number: 499-75-2). 
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Figure 41. GC-MS profile of the fraction P4B-D-25. 
Table 31. 1H and 13C NMR data for P4B-D-25 (5-isopropyl-2-methylphenol). 
Chemical Shift, ppm 
Literature value 
[32] Position 
1H 13C 13C 
1 - 153.9 153.5  s   (0.13) 
2 - 121.1 121.5  s  (0.08) 
3 7.04  d (7.65) 131.0 131.0  d   (0.54) 
4 6.73  dd  (1.5, 7.65) 118.9 119.1  d   (0.49) 
5 - 148.6 148.4  s  (0.08) 
6 6.67  d  (1.4) 113.2 113.5  d   (0.33) 
2-CH3 2.23  s 15.5 15.4  q  (0.27) 
2` 2.84       (6.9) 33.9 33.7  d  (0.36) 
1`  24.2 23.9  q  (1.0) 
 
 80 
4.4.2.4. Identification of P4B-D-16 as m-mentha-4,6-dien-8-ol 
Compound isolated from the fraction P4B-D-16 was elucidated as m-mentha-4,6-dien-8-ol 
with RT of 18.15 min, a molecular formula C10H16O and molecular weight of 152.24 g/mol 
which corresponds to m/z from the GC-MS profile (Figure 43). The structure is shown in 
Figure 42 and the 1H and 13C NMR data in Table 33. The compound was found in the crude 
oil in the amount of 3.74%. It was not found in the Dictionary of Natural Products [33] and to 
the knowledge of the author of this thesis, no activity of this compound was reported. 
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Figure 42. Structure of the m-mentha-4,6-dien-8-ol. 
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Figure 43. GC-MS profile of the fraction P4B-D-16. 
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Table 32. 1H and 13C NMR data for P4B-D-16 (m-mentha-4,6-dien-8-ol). 
Chemical Shift, ppm 
Position 
1H 13C 
1 1.21 27.3 
2 - 73.5 
3 2.37 45.4 
4 2.17, 1.25 30.1 
5 - 136.0 
6 5.63 118.7 
7 5.94 126.1 
8 5.63 123.5 
5-CH3 23.5 23.5 
4.4.2.5. Pharmacology of the P4B-D fractions 
ORAC assay was done for all extracted P4B-D fractions. Results are shown in Table 29. The 
highest antioxidant activity had fractions 14, 26 and 27. Fractions 26 and 27 contained 
carvacrol as a major compound, but also a high percentage (>20%) of another compound that 
could not be identified. Carvacrol was also the major component in fraction 25, but its ORAC 
value was not as high. This could suggest that the unidentified component in 26 and 27 
contributed a lot to their high activity. However, because of the lack of material no further 
fractionation has been carried out.    
High ORAC value of the fraction 14 could not be explained only from its GC-MS profile, but 
UV profiles (Figure 44) suggest the presence of an aromatic compound, which could be 
responsible for the antioxidant activity. The compound was found in the region of 
monoterpenes and it had [M+1]+ of 151.2. Cytotoxic activity was not observed in the P4B-D 
fractions. 
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Table 33. ORAC results of P4B-D fractions. 
Sample ORAC value μmol TE/g  RSD (%)  
P4B-D 2535 ± 410 16.17 
P4B-D-8 139 ± 43 31.16 
P4B-D-9 474 ± 76 16.01 
P4B-D-11 2493 ± 207 8.31 
P4B-D-13 735 ± 137 18.64 
P4B-D-14 8008 ± 1139 14.22 
P4B-D-15 2667 ± 2150 8.06 
P4B-D-16 874 ± 179 20.43 
P4B-D-19 1221 ± 186 15.26 
P4B-D-20 2065 ± 168 8.12 
P4B-D-21 995 ± 192 19.27 
P4B-D-25 4480 ± 764 17.04 
P4B-D-26 7203 ± 2061 28.62 
P4B-D-27 6959 ± 1322 19.00 
P4B-D-28 2834 ± 820 28.95 
 
 
 
Figure 44. UV spectra at 210, 280, 360 and 500nm and LCMS profile of the P4B-D-14. 
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4.4.3. Fraction P4B-H 
The UV spectra of the P4B-H fraction at 210 and 280nm and solvent gradient of the mobile 
phases are shown in the chromatogram (Figure 45). Altogether 48 fractions were collected, 
dried under nitrogen, extracted with hexane and analysed in LCMS. The LCMS analysis of 
the fraction P4B-H-16 (which corresponds to the first large peak in the chromatogram) 
showed a component with a molecular peak 223.2 which correspond to the [M+1]+ of 
intermedeol. Unfortunately, isolation of this component was not successful due to the small 
amount of P4B-H fraction. 
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Figure 45. Prep. HPLC Chromatogram of the P4B-H fraction (Method :ELENA-H). 
4.4.4. Fraction P4B-I 
The chromatogram of the P4B-I fraction showed UV spectra at 210 and 280nm and solvent 
gradient of the mobile phases (Figure 46). GC-MS analysis of the fractions did not show any 
volatile compounds but the LCMS profiles of fractions P4B-I-13 and P4B-I-26 were 
unexpected. The UV at 210nm and TIC of P4B-I-13 is shown in Figure 47. UV at 210nm 
suggests absence of chromophores and the TIC gave [M+1]+ of 279.2 which correspond to a 
fatty acid with molecular formula of C18H20O2. The chromatographic profile of P4B-I-28 
(Figure 48) showed component with [M+1]+ of 392.3, which is characteristic for a plasticizer. 
These findings could suggest a contamination of the sample. 
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Figure 46. Prep. HPLC of the P4B-I fraction (Method: ELENA6). 
 
min0 2.5 5 7.5 10 12.5 15 17.5 20 22.5
mAU
0
250
500
750
1000
1250
1500
1750
2000
 DAD1 A, Sig=210,8 Ref=off (M:\LCMSDATA\DATA\0909DATA\090915\P4I-13.D)
min0 2.5 5 7.5 10 12.5 15 17.5 20 22.5
0
100000
200000
300000
400000
 MSD1 TIC, MS File (M:\LCMSDATA\DATA\0909DATA\090915\P4I-13.D)    APCI, Pos, Scan, Frag: 150, "Positive150"
 
nm200 300 400 500
mAU
-300
-250
-200
-150
-100
-50
*DAD1, 14.556 (309 mAU, - ) Ref=14.529 of P4I-13.D
 m/z100 200 300
0
20
40
60
80
100
*MSD1 SPC, time=14.567 of M:\LCMSDATA\DATA\0909DATA\090915\P4I-
Max: 265536
 2
79
.2
 2
80
.3
 2
61
.3
 
Figure 47. UV spectrum at 210nm and LCMS profile of P4B-I-13. 
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Figure 48. UV spectrum at 210nm and LCMS profile of P4B-I-28. 
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5. Plectranthus nitidus (P3) 
Plectranthus nitidus oil was intensely red in colour, more viscous than the rest of the oils and 
growth of red crystals was observed in the vial. The crystals were separated from the rest of 
the oil and washed with cold methanol. Methanol was evaporated under nitrogen and the 
crystals were dried in the freeze drier over night. The rest of the oil was diluted in 100% 
methanol and fractionated by preparative HPLC. 
5.1.  Preparative HPLC of P. nitidus oil (P3) 
The HPLC chromatographic profile of P. nitidus oil (P3) is shown in Figure 49. A total of 67 
fractions were collected. Fractions were mostly yellow coloured, except for two fractions that 
were intense red in colour (P3-31, P3-32) and another two that were reddish-orange (P3-26, 
P3-27). Preliminary LCMS analysis was carried out for all the fractions. Analysis showed that 
fractions P3-31 and P3-32 were the same as the red crystal that was separated at the beginning 
and that the other reddish compound from fractions P-26 and P-27 was different. Nine 
relatively pure fractions were selected, dried under nitrogen and extracted with chloroform. 
Yields are shown in Table 34. The fractions and the red crystal were analyzed by 1H NMR 
spectroscopy. Analysis showed that the red crystals and fraction P3-36 were pure enough for 
further NMR analysis.  
Overlaid UV chromatograms at 210nm wavelength of the crude oil, P3-31 (that was the same 
as the red crystal) and P3-36 are shown in Figure 50. The overlaid LCMS profiles are shown 
in Figure 51. (The single chromatograms of the nine extracted fractions and the crystal (P3-
31) are shown in Appendix 3.) The UV profiles were characteristic of diterpenes, a fact which 
is in correlation with GC-MS finding. Molecular ions of the fractions showed m/z of 345.2 
[M+1]+ for fraction P3-20; 288.2 and 331.2 [M+1]+  for fractions P3-26 and P3-27; 315.2 
[M+1]+  for fractions P3-31 and P3-33 and 272.3 [M+1]+  for fraction P3-36.  
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Figure 49. Prep. HPLC of the P3 oil (Method:ELENA-H).  
Table 34.    Yields of the P3-Fractions. 
Fraction Yield (g) 
P3-20 0.0016 
P3-25 0.0031 
P3-26 0.0090 
P3-27 0.0113 
P3-29 0.0035 
P3-35 0.0065 
P3-36 0.0074 
P3-37 0.0020 
P3-40 0.0022 
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Figure 50. Overlaid UV spectra at 210nm wavelength of the crude oil, P3-31 and P3-36.  
 
Figure 51. Overlaid LCMS spectra of the crude oil, P3-31 and P3-36. 
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5.1.1.  Identification of P3 crystal as 12-hydroxy-6,8,12-abietatriene-11,14-
dione  
The red crystals of the P.nitidus oil were run on the NMR and the 1H and 13C NMR spectra 
were compared with the ones of the red crystals that were isolated from P. graveolens by 
Leema Marangattil. The comparison showed that the crystals were the same and the 
compound was identified as 12-hydroxy-6,8,12-abietatriene-11,14-dione (Figure 52). The 
molecular formula is C20H26O3 and the MS data of C20H26O3 [M+1]=315.2 agreed to this 
molecular formula (Figure 53).  
Marangattil reported significant cytotoxic activity of this compound against P388 mammalian 
cell line (personal communication). This was the major compound and it is responsible for the 
red colour of the oil.  
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Figure 52. Structure of P3 crystal (12-hydroxy-6,8,12-abietatriene-11,14-dione). 
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Figure 53. LCMS profile of the P3 crystal. 
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5.1.1.1. Identification of P3-36 as 7,9(11)-abietadiene-13-ol   
The 1H and 13C NMR data of P3-36 are shown in Table 35. The compound was elucidated as 
7,9(11)-abietadiene-13-ol, with molecular formula of C20H32O and molecular weight of 
288.47 g/mol. The structure is shown in Figure 54 and the LCMS profile in Figure 55. This 
compound was one of the major components of the oil. It was yellow coloured and had oily 
consistence. It was not found in the Dictionary of Natural Products [33] and could possibly be 
novel. However further NMR analysis is needed to confirm the structure and thus the 
identification was deemed as tentative. 
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Figure 54. Structure of the P3-36 (7,9(11)-abietadiene-13-ol). 
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Figure 55. LCMS prfile of the fraction P3-36. 
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Table 35. The 1H and 13C NMR data for P3-36 (13-hydroxyl-7,9-abietadiene). 
Chemical Shift, ppm 
Position 
1H 13C 
1 1.91  br d  12.75 
1.31  t  3.95, 13.0 
37.5 
2 1.64 
1.54 
19.2 
3 1.43  br dd 1.65, 13.05 
1.17  td  3.9/3.7, 13.55 
42.4 
4 - 33.42 
5 1.22  dd  4.2, 11.8 49.3 
6 2.01-2.17  m 24.2 
7 5.59  br d  5.6 126.1 
8 - 130.2 
9 - 148.0 
10 -  
11 5.43 br 115.3 
12 2.28-2.39  m 
2.01-2.17  m 
36.3 
13 - 72.5 
14 2.28-2.39  m 41.2 
15 1.74  heptet 6.9 35.2 
16 0.96  d  3.5 17.2 
17 0.94  d  3.5 17.0 
18 0.93  s 22.4 
19 0.89  s 33.39 
20 1.0   s 22.3 
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6. Summary and recommendations 
The chemical profiles of the Plectranthus oils are summarized in Table 36. Although all of 
the profiled species belong to the same genus and are common for the eastern Australian 
coast, there is no correlation in their chemical profiles. Pharmacological results (Figure 56) 
showed that ornamental Plectranthus had the highest antioxidant activity, probably due to its 
high carvacrol content and Plectranthus nitidus had the highest cytotoxic activity which could 
be attributed to diterpenes that were present in the oil. 
 
Table 36. Summarized table of the Plectranthus species oil profiles 
  
P. graveolens P. suaveolens P. nitidus P.sp. 'Hahn Tableland' 
ornamental 
Plectranthus 
Monoterpene + +  + + 
Sesquiterpene + +   + 
Diterpene +  +   
 
 
Figure 56. Summarized pharmacology results of the Plectranthus oils. 
 
Plectranthus sp. ‘Hahn Tableland’ was fractionated and the fractions were screened for 
antioxidant and cytotox activity. Six compounds were isolated from the fractions P4B-D and 
P4B-C (Table 37). Out of 5 compounds that could not have been identified in the crude oil 
two were isolated and identified. They are m-mentha-4,6-dien-8-ol, with RT 18.15 min and 
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3.74% relative distribution in the crude oil and m-cymen-8-ol with RT 18.42 min and 3.67% 
relative distribution in the crude oil. Another isolated compound was 3-caren-2-one that was 
not present in the crude oil and is possibly oxidation product of the major component from the 
oil, δ-3-carene. Carvacrol was isolated and found to be responsible for the highest antioxidant 
activity of the P4B-D fraction. Compounds m-cymen-8-ol, m-mentha-4,6-dien-8-ol, 3,6,6-
trimethyl-2,4-cycloheptadien-1-one have not been reported in this genus before.  
 
Table 37. Isolated compounds from the P4B oil. 
Fraction Compound 
Molecular 
formula MW (g/mol)
P4B-C-14 3-Caren-2-one C10H14O 150.22
P4B-C-18 m-Cymen-8-ol C10H14O 150.22
P4B-C-18, 
P4B-D-8 
3,6,6-Trimethyl-2,4-cycloheptadien-1-
one C10H14O 150.22
P4B-D-14 Carvone C10H14O 150.22
P4B-D-16 m-Mentha-4,6-dien-8-ol C10H16O 152.24
P4B-D-25, 
P4B-D-27 Carvacrol C10H14O 150.22
  
The volatile oil of the P. sp. ‘Hahn Tableland’ has shown moderate antioxidant and cytotoxic 
activity, but further analysis on its antimicrobial properties would have been  relevant, since 
its components (limonene, carvone,, carvacrol) were already reported as antimicrobial [34], 
[35]. Also α-pinene and δ-3-carene were reported to have antifungal properties [36].  
Plectranthus nitidus oil was fractionated by preparative HPLC and at the time of writing two 
compounds were identified by NMR. The red crystals were identified as 12-hydroxy-6,8,12-
abietatriene-11,14-dione and that was also the major compound of the oil. Another compound 
was 13-hydroxyl-7,9-abietadiene, but its structure has to be reconfirmed. It has not been 
reported in Dictionary of Natural Products and could possibly be novel. Crude oil showed 
magnificent cytotoxic activity and further analysis on the pure compounds is planned. 
This was the first study on chemistry and pharmacological activity of this species. In future 
work the method of separation should be improved in order to get more pure compounds. 
Also investigation of cytotoxic activity on different cell lines could give more information 
about cytotoxic activity of this plant. Anti-insecticidal activity was reported in P.graveolens 
[4], and it was attributed to its diterpenes content. Since P. nitidus has very similar diterpenes 
profile to P. graveolens it could also have similar anti-insecticidal properties and is worth 
investigating.  
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Figure 57.  Identified compounds from P.nitidus oil shown on the UV chromatogram at 
210nm wavelength. 
 
This study was based upon analysis of the volatile oils of the Plectranthus species. The 
examination of the leaf extracts with different solvents would have been relevant and could 
possibly reveal new, more polar components that were not present in the volatile oil.  
 
 
7,9(11)-abietadiene-13-ol 
12-hidroxy-6,8,12-
abietatriene-11,14-
dione  
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Appendix 1  
Detailed cytotoxic results 
 
  
Appendix Figure 1. Cytotoxic results of Plectranthus oils (P1-P6). 
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Appendix Table 1. Cytotoxic results of Plectranthus oils. 
Sample 
Conc. 
(µg/mL) 
Inhib. Rep1
(%) 
Inhib. Rep2
(%) 
Average 
Inhibition 
 
IC50 
(µg/mL) 
curcumin 100.000 99 99 99 
  50.000 95 99 97 
  25.000 90 91 91 
  12.500 67 78 73 
  6.250 23 16 20 
  3.125 10 -14 -2 
  1.563 21 -19 1 
 
 
 
9.53 
chlorambucil 600.000 99 99 99 
  300.000 96 96 96 
  150.000 74 78 76 
  75.000 48 36 42 
  37.500 18 7 13 
  18.750 15 8 12 
  9.375 -9 -2 -6 
 
 
 
86.89 
 
P1 117.000 86 88 87 
  58.500 16 43 30 
  29.250 0 8 4 
  14.625 10 7 9 
  7.313 7 3 5 
  3.656 6 -11 -3 
  1.828 7 -16 -5 
 
 
 
60 
P2 137.000 98 74 86 
  68.500 49 32 41 
  34.250 22 15 19 
  17.125 28 2 15 
  8.563 7 -2 3 
  4.281 16 -12 2 
  2.141 11 -34 -12 
 
 
 
61.58 
 
P3 109.000 100 99 100 
  54.500 80 81 81 
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Sample 
Conc. 
(µg/mL) 
Inhib. Rep1
(%) 
Inhib. Rep2
(%) 
Average 
Inhibition 
 
IC50 
(µg/mL) 
  27.250 37 35 36 
  13.625 28 10 19 
  6.813 14 -4 5 
  3.406 9 -4 3 
  1.703 4 -18 -7 
 
31.52 
P4A 160.000 61 11 36 
  80.000 33 27 30 
  40.000 16 5 11 
  20.000 1 13 7 
  10.000 10 -4 3 
  5.000 8 -8 0 
  2.500 3 -15 -6 
 
 
 
120 
P4B 147.000 70 61 66 
  73.500 43 32 38 
  36.750 14 28 21 
  18.375 11 12 12 
  9.188 4 3 4 
  4.594 5 -1 2 
  2.297 4 -7 -2 
 
 
 
97.29 
P6A 134.000 26 20 23 
  67.000 7 -1 3 
  33.500 -9 -4 -7 
  16.750 11 -10 1 
  8.375 6 -14 -4 
  4.188 3 -19 -8 
  2.094 -3 38 18 
 
 
 
182.63 
P6B 150.000 18 24 21 
  75.000 -14 18 2 
  37.500 -10 3 -4 
  18.750 -2 3 1 
  9.375 8 -4 2 
 
 
 
209.44 
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Sample 
Conc. 
(µg/mL) 
Inhib. Rep1
(%) 
Inhib. Rep2
(%) 
Average 
Inhibition 
 
IC50 
(µg/mL) 
  4.688 13 -6 4 
  2.344 3 -10 -4 
 
 
 
 
Appendix Figure 2. Cytotoxic results of P4B fractions. 
Appendix Table 2. Cytotoxic results of P4B fractions. 
Sample Conc. 
(µg/mL) 
 
Inh. Rep1 
(%) 
Inh. Rep2 
(%) 
Average 
Inhibition 
IC50 
(µg/mL)
CURCUMIN 100.000 74% 80% 77%   
  50.000 41% 53% 95%   
  25.000 16% 18% 92%   
  12.500 6% 1% 81% 54 
  6.250 4% -8% 49%   
  3.125 -4% -19% 31%   
  1.563 -3% -16% 7%   
P4B 147.000 70% 61% 66%   
  73.500 43% 32% 38%   
  36.750 14% 28% 21%   
  18.375 11% 12% 12% 146 
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Sample Conc. 
(µg/mL) 
 
Inh. Rep1 
(%) 
Inh. Rep2 
(%) 
Average 
Inhibition 
IC50 
(µg/mL)
  9.188 4% 3% 4   
  4.594 5% -1% 2   
  2.297 4% -7% -2   
B 94.000 46% 50% 48%   
  47.000 18% 34% 26%   
  23.500 -3% 1% -1%   
  11.750 -7% -12% -10% >200 
  5.875 7% -21% -7%   
  2.938 -5% -11% -8%   
  1.469 -20% -25% -23%   
C 95.000 68% 64% 66%   
  47.500 37% 33% 35%   
  23.750 14% 12% 13%   
  11.875 -5% -11% -8% 48 
  5.938 -3% -5% -4%   
  2.969 -6% -21% -14%   
  1.484 -20% -30% -25%   
D 98.000 64% 66% 65%   
  49.000 49% 40% 45%   
  24.500 11% 13% 12%   
  12.250 -5% -4% -5% 48 
  6.125 -2% -5% -4%   
  3.063 -6% -30% -18%   
  1.531 -7% -36% -22%   
E 130.000 96% 96% 96%   
  65.000 60% 63% 62%   
  32.500 19% 43% 31%   
  16.250 6% 11% 9% 36 
  8.125 -11% -13% -12%   
  4.063 -16% -14% -15%   
  2.031 -26% -24% -25%   
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Sample Conc. 
(µg/mL) 
 
Inh. Rep1 
(%) 
Inh. Rep2 
(%) 
Average 
Inhibition 
IC50 
(µg/mL)
F 117.000 76% 82% 79%   
  58.500 51% 51% 51%   
  29.250 26% 27% 27%   
  14.625 15% 13% 14% 29 
  7.313 -4% -7% -6%   
  3.656 -4% -21% -13%   
  1.828 -32% -33% -33%   
G 91.000 83% 81% 82%   
  45.500 43% 48% 46%   
  22.750 20% 17% 19%   
  11.375 -2% -6% -4% 38 
  5.688 -1% -13% -7%   
  2.844 -6% -18% -12%   
  1.422 -19% -35% -27%   
H 135.000 55% 61% 58%   
  67.500 20% 37% 29%   
  33.750 -4% 10% 3%   
  16.875 -8% 7% -1% 91 
  8.438 -9% -8% -9%   
  4.219 -21% -12% -17%   
  2.109 -26% -16% -21%   
I 82.000 50% 49% 50%   
  41.000 22% 38% 30%   
  20.500 -1% 8% 4%   
  10.250 -11% -17% -14% 64 
  5.125 -11% -19% -15%   
  2.563 -1% 11% 5%   
  1.281 -16% -35% -26%   
K 108.000 10% 34% 22%   
  54.000 13% 28% 21%   
  27.000 9% 28% 19%   
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Sample Conc. 
(µg/mL) 
 
Inh. Rep1 
(%) 
Inh. Rep2 
(%) 
Average 
Inhibition 
IC50 
(µg/mL)
  13.500 5% -6% -1% >200 
  6.750 11% -2% 5%   
  3.375 9% 18% 14%   
  1.688 2% 5% 4%   
M 140.000 10% 34% 22%   
  70.000 13% 28% 21%   
  35.000 9% 28% 19%   
  17.500 5% -6% -1% >200 
  8.750 11% -2% 5%   
  4.375 9% 18% 14%   
  2.188 2% 5% 4%   
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Appendix 2 -  
Detailed composition of the P4B-C and P4B-D fractions 
Appendix Table 3. Chemical composition of the P4B-C fractions. 
Fraction Component RT(min) AREA (%) Match (%) 
 P4B-C-7 o-Cresol 15.65 26.14 98 
  Eucarvone 19.33 9.44 81 
  Unidentified 20.53 4.94 45 
  Eucarvone   21.28 59.48 90 
P4B-C-8         
  o-Cresol 15.65 12.48 98 
  Eucarvone 19.33 3.70 80 
  Eucarvone   21.29 69.04 90 
  Unidentified 21.34 2.86 50 
P4B-C-11         
  Verbenone 19.30 67.81 97 
P4B-C-14         
  cis-Linalool oxide  16.32 2.44 91 
  Car-3-en-2-one 20.03 89.40 97 
P4B-C-15         
  
p-Methyl-
acetophenone 18.45 16.12 97 
  
p-Methyl-
acetophenone 18.79 17.52 97 
  Unidentified 19.81 2.37 72 
  Car-3-en-2-one 20.01 59.72 98 
P4B-C-16         
  p-Cymen-8-ol 18.40 4.23 87 
  
p-Methyl-
acetophenone 18.45 23.00 95 
  Cryptone  18.88 7.49 95 
  Car-3-en-2-one 20.00 10.98 97 
  Unidentified 20.21 9.55 50 
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Fraction Component RT(min) AREA (%) Match (%) 
  trans-Carvone oxide 20.96 27.47 95 
  
6-Hydroxy-
carvotanacetone 21.21 7.59 78 
P4B-C-18         
  Unidentified 18.24 5.27 45 
  p-Cymen-8-ol 18.43 33.71 83 
  p-Cymen-8-ol 18.61 1.41 90 
  Eucarvone    19.36 54.94 74 
P4B-C-19         
  p-Cymen-8-ol 18.43 24.08 83 
  Unidentified 18.56 14.14 59 
  p-Cymen-8-ol 18.61 5.50 83 
  Eucarvone    19.36 51.24 74 
P4B-C-20         
  Unidentified 18.24 2.71 45 
  p-Cymen-8-ol 18.41 20.10 83 
  Unidentified 18.55 16.90 59 
  p-Cymen-8-ol 18.61 8.34 90 
  Eucarvone    19.35 51.2 83 
P4B-C-21         
 p-Cymen-8-ol 18.4 13.41 90 
 Unidentified 18.55 21.33 59 
 o-Cymen-8-ol 18.61 9.98 90 
 Eucarvone    19.34 46.1 83 
 Eucarvone    19.41 5.31 81 
P4B-C-22         
  p-Cymen-8-ol 18.4 11.24 87 
  o-Cymen-8-ol 18.6 19.7 90 
  Unidentified 19.12 4.16 64 
  Chrysanthenone 19.33 39.9 83 
  Eucarvone 19.41 25 76 
P4B-C-23         
  p-Cymen-8-ol 18.4 4.46 90 
 107 
Fraction Component RT(min) AREA (%) Match (%) 
  Unidentified 18.55 14.73 59 
  o-Cymen-8-ol 18.6 11.4 90 
  Eucarvone 19.33 14.81 87 
  Eucarvone 19.41 49.91 87 
P4B-C-24         
  Eucarvone 19.41 100 70 
P4B-C-27         
  Carvone 19.85 65.85 90 
  p-Cymen-7-ol 20.68 9.49 97 
P4B-C-28         
  Carvone 19.85 63.74 95 
  p-Cymen-7-ol 20.68 9.23 83 
  Eucarvone 21.95 19.73 68 
P4B-C-32         
  
p-Mentha-1,5-dien-
8-ol 
18.14 97.04 80 
P4B-C-37         
  
p-Mentha-1,5-dien-
8-ol 
8.31 36.65 83 
  Unidentified 19.06 11.14 64 
  trans-Carveol 19.22 52.21 97 
 
Appendix Table 4. Chemical composition of the P4B-D fractions. 
Fraction Component RT(min) 
AREA 
(%) 
Match 
(%) 
P4B-D-8 Carvone 19.85 63.98 94 
  Unidentified 20.68 5.79 64 
  Eucarvone 21.95 10.07 90 
P4B-D-9         
  Eucarvone 19.36 75.81 87 
P4B-D-13         
  p-Cymen-8-ol 18.41 22 83 
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Fraction Component RT(min) 
AREA 
(%) 
Match 
(%) 
  Unidentified 18.24 5.5  45 
      
4-Ethyl-3,4-dimethyl-2,5-
cyclohexadien-1-one 
19.36 67.2 72 
  Eucravone 21.28 2.84 90 
P4B-D-14         
  Carvone 19.86 50.84 90 
  Eucarvone 21.96 39.45 90 
P4B-D-15         
  Unidentified 18.15 84.44 59 
  o-Piperitone 21.96 7.32 80 
P4B-D-16         
  Unidentified 18.15 93.67 64 
P4B-D-19         
  trans-Carveol 19.23 19.13 95 
  p-Mentha-1,5-dien-8-ol 20.75 4.37 72 
  p-Mentha-1(7),2-dien-8-ol 20.99 11 72 
P4B-D-20         
  trans-Carveol 19.24 26.86 96 
  Unidentified 19.51 4.83 62 
P4B-D-21         
  trans-Carveol 19.23 65.66 95 
  cis-Carveol 19.51 34.34 96 
P4B-D-22         
  trans-Carveol 19.23 49.43 86 
  Unidentified 19.51 50.57 59 
P4B-D-25         
  Carvacrol 20.64 88.33 96 
P4B-D-26         
  Carvacrol acetate 20.49 20.25 94 
  Carvacrol 20.64 79.75 95 
P4B-D-27         
  Carvacrol  20.49 30.79 94 
 109 
Fraction Component RT(min) 
AREA 
(%) 
Match 
(%) 
  Carvacrol 20.63 69.21 93 
P4B-D-28         
  Unidentified 18.8 16.35 64 
  Carvacrol 20.49 37.54 91 
  Thymol 20.62 46.11 83 
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Appendix 3 - 
Chromatographic profiles of the P. nitidus fractions 
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Appendix Figure 3. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-20. 
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Appendix Figure 4. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-25. 
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Appendix Figure 5. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-26. 
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Appendix Figure 6. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-27. 
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Appendix Figure 7. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-29. 
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Appendix Figure 8. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-31. 
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Appendix Figure 9. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-35. 
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Appendix Figure 10. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-36. 
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Appendix Figure 11. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-37. 
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Appendix Figure 12. UV profile at 210, 280, 360, 500nm and LCMS profile of the P3-40. 
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